GLP-1 Market
LLY $1136.11 ▼ -0.2% NVO $42.53 ▼ -2.1% PFE $27.55 ▼ -0.6% VKTX $29.95 ▼ -5.0% KLRA $13.45 ▼ -2.2% GPCR $38.95 ▲ +1.3% RHHBY $54.90 ▲ +0.2%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Dapagliflozin

Company
University Hospital Tuebingen
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
72 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

72 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 16, 2026

Find a Clinical Trial Near Me

See recruiting studies for Dapagliflozin and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT04591639

    The DAPA-MEMRI Trial

    Not yet reported University of Edinburgh 160 participants Est. completion 2028-07-28 1 site
    Heart failure Other conditions: Diabetic Cardiomyopathies
    View official trial listing →
  • Recruiting NCT NCT04662723

    Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.

    Not yet reported Fondazione Schena 878 participants Est. completion 2028-12-31 2 sites
    Other conditions: Glomerulonephritis, Immunoglobulin A Nephropathy
    View official trial listing →
  • Recruiting NCT NCT05174052

    Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)

    Not yet reported University of Oklahoma 28 participants Est. completion 2027-12 1 site
    Other conditions: Diabetes Mellitus, Atrial Fibrillation
    View official trial listing →
  • Recruiting NCT NCT05305911

    Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI

    Not yet reported Minneapolis Heart Institute Foundation 81 participants Est. completion 2028-12 1 site
    Other conditions: Heart Attack, Enlarged Heart
    View official trial listing →
  • Recruiting NCT NCT05345327

    SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes

    Not yet reported The George Institute 994 participants Est. completion 2026-06-30 8 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Recruiting NCT NCT05359263

    Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKD

    Not yet reported Tor Biering-Sørensen 222 participants Est. completion 2025-02-18 1 site Stand-alone
    Chronic kidney disease
    View official trial listing →
  • Recruiting NCT NCT05390892

    PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

    Not yet reported Brigham and Women's Hospital 6000 participants Est. completion 2029-03-01 36 sites
    Cardiovascular disease Other conditions: Type2Diabetes
    View official trial listing →
  • Recruiting NCT NCT05521984

    Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)

    Not yet reported Washington University School of Medicine 20 participants Est. completion 2031-06-30 1 site Stand-alone
    Other conditions: Pediatric Brain Tumor, Pediatric Solid Tumor
    View official trial listing →
  • Recruiting NCT NCT05770687

    SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study

    Kiyuk Chang 1000 participants Est. completion 2026-12-31 1 site
    Cardiovascular diseaseType 2 diabetes
    View official trial listing →
  • Recruiting NCT NCT05986136

    Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease

    Not yet reported, Not yet reported Mostafa Bahaa 50 participants Est. completion 2028-07-20 1 site
    Other conditions: Inflammatory Bowel Diseases
    View official trial listing →
  • Recruiting NCT NCT05989347

    Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy

    Not yet reported Yale University 20 participants Est. completion 2027-12 1 site Stand-alone
    Other conditions: Breast Cancer, Hyperinsulinism, HER2-negative Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06054035

    SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes

    Not yet reported University Hospital Tuebingen 170 participants Est. completion 2027-09-30 9 sites Stand-alone
    Prediabetes Other conditions: Type2diabetes, Renal Failure
    View official trial listing →
  • Recruiting NCT NCT06091475

    Therapy to Maintain Remission in Dilated Cardiomyopathy

    Not yet reported Imperial College London 50 participants Est. completion 2026-09-15 1 site Stand-alone
    Heart failure Other conditions: Cardiomyopathy, Dilated, Cardiomyopathies, Heart Diseases
    View official trial listing →
  • Recruiting NCT NCT06140537

    Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients

    Not yet reported University of Colorado, Denver 80 participants Est. completion 2028-12-31 1 site Stand-alone
    Other conditions: Kidney Transplant; Complications, Vascular Diseases, Diabetes
    View official trial listing →
  • Recruiting NCT NCT06142474

    SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning

    Not yet reported National Taiwan University Hospital 450 participants Est. completion 2030-10-09 1 site Stand-alone
    Heart failure Other conditions: Ventilator Lung
    View official trial listing →
  • Recruiting NCT NCT06155604

    SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease

    Not yet reported The University of Hong Kong 150 participants Est. completion 2026-12-31 1 site Stand-alone
    Chronic kidney disease Other conditions: Lupus Nephritis
    View official trial listing →
  • Recruiting NCT NCT06174753

    Dapagliflozin in STEMI

    Not yet reported Ottawa Heart Institute Research Corporation 256 participants Est. completion 2027-12 1 site Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Recruiting NCT NCT06286878

    Pleiotropic Effects of Dapagliflozin in Patients With Acute Coronary Syndromes

    Not yet reported, Not yet reported University of Sao Paulo 80 participants Est. completion 2025-07-30 1 site Stand-alone
    Cardiovascular disease Other conditions: Acute Coronary Syndrome, Diabetes, Ventricular Dysfunction
    View official trial listing →
  • Recruiting NCT NCT06364930

    SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus

    Not yet reported Chinese University of Hong Kong 412 participants Est. completion 2031-03-30 1 site
    Other conditions: Chronic Hepatitis B
    View official trial listing →
  • Recruiting NCT NCT06398977

    Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients

    Not yet reported Sichuan Academy of Medical Sciences 70 participants Est. completion 2026-12-31 1 site
    Other conditions: Peritoneal Dialysis Complication, Renal Function Aggravated, Sodium-glucose Co-transporter-2 Inhibitors
    View official trial listing →
  • Recruiting NCT NCT06420167

    DapagliFLOzin in Renal AL Amyloidosis (FLORAL)

    Not yet reported Barbara Ann Karmanos Cancer Institute 20 participants Est. completion 2028-04 1 site Stand-alone
    Other conditions: Renal AL Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT06520891

    "The Effect of The Combination Therapy of Statin and SGLT2i in The Treatment of Ischemic Heart Disease"

    Fayoum University 90 participants Est. completion 2025-12-30 1 site
    Other conditions: 2 Drugs Are Statin and SGLT2i
    View official trial listing →
  • Recruiting NCT NCT06562582

    STunning in Acute Myocardial Infarction - BAS

    Not yet reported Vastra Gotaland Region 120 participants Est. completion 2027-12-31 1 site
    Other conditions: Myocardial Infarct
    View official trial listing →
  • Recruiting NCT NCT06572215

    DYNAMic Renal Assessment: NOvel Methods to Assess KIDNEY Functional Reserve

    King's College Hospital NHS Trust 44 participants Est. completion 2027-12-31 1 site
    Chronic kidney disease
    View official trial listing →
  • Recruiting NCT NCT06642272

    A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record

    Not yet reported Herlev and Gentofte Hospital 17200 participants Est. completion 2028-12-31 12 sites
    Type 2 diabetesHeart failureChronic kidney disease
    View official trial listing →
  • Recruiting NCT NCT06647745

    A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension

    Not yet reported THPharm Corp. 221 participants Est. completion 2026-12-01 2 sites Stand-alone
    Type 2 diabetes Other conditions: Hypertension
    View official trial listing →
  • Recruiting NCT NCT06649162

    A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy

    Boryung Pharmaceutical Co., Ltd 10000 participants Est. completion 2027-03 2 sites
    Type 2 diabetes
    View official trial listing →
  • Recruiting NCT NCT06676384

    Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?

    Not yet reported Christian Medical College, Vellore, India 585 participants Est. completion 2029-08 12 sites
    Other conditions: IgA Nephropathy, Renal Insufficiency, Chronic, IgA Vasculitis, IGA Glomerulonephritis
    View official trial listing →
  • Recruiting NCT NCT06677060

    Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

    Not yet reported AstraZeneca 11300 participants Est. completion 2029-12-17 957 sites Stand-alone
    Heart failure
    View official trial listing →
  • Recruiting NCT NCT06742723

    A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

    Not yet reported AstraZeneca 5000 participants Est. completion 2029-12-18 771 sites Stand-alone
    Chronic kidney disease
    View official trial listing →
  • Recruiting NCT NCT06772168

    Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia

    Not yet reported CMG Pharmaceutical Co. Ltd 240 participants Est. completion 2027-02-01 24 sites Stand-alone
    Type 2 diabetes Other conditions: Dyslipidemia
    View official trial listing →
  • Recruiting NCT NCT06785116

    A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)

    Not yet reported University of Michigan 200 participants Est. completion 2028-08 1 site Stand-alone
    Other conditions: Gestational Hypertension, Hypertension in Pregnancy, Pre-Eclampsia, Superimposed Pre-Eclampsia, Cardiovascular Complication
    View official trial listing →
  • Recruiting NCT NCT06843902

    Improving Coronary Vascular Health in Women

    Not yet reported Massachusetts General Hospital 80 participants Est. completion 2029-06 1 site Stand-alone
    Other conditions: HIV-1-infection, Coronary Microvascular Dysfunction, Metabolic Disease
    View official trial listing →
  • Recruiting NCT NCT06845163

    Randomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients With Diabetic Macular Edema

    Not yet reported Alexandria University 56 participants Est. completion 2026-08 1 site Stand-alone
    Other conditions: Diabetic Macular Edema, Center-involved Diabetic Macular Edema
    View official trial listing →
  • Recruiting NCT NCT06868797

    Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List

    Not yet reported Central Hospital, Nancy, France 103 participants Est. completion 2027-09-12 11 sites
    Heart failure
    View official trial listing →
  • Recruiting NCT NCT06887062

    Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)

    Not yet reported University of Edinburgh 60 participants Est. completion 2027-07-01 1 site Stand-alone
    Other conditions: Large Vessel Vasculitis, Giant Cell Arteritis (GCA), Takayasu Arteritis
    View official trial listing →
  • Recruiting NCT NCT06890143

    The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children

    Not yet reported Children's Hospital of Fudan University 44 participants Est. completion 2027-03-31 1 site Stand-alone
    Other conditions: Pediatric Hereditary Kidney Diseases
    View official trial listing →
  • Recruiting NCT NCT06897605

    Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients

    Not yet reported Mansoura University 80 participants Est. completion 2025-10 1 site Stand-alone
    Chronic kidney disease Other conditions: Anemia, Kidney Disease, Chronic
    View official trial listing →
  • Recruiting NCT NCT06929169

    Cardiovascular Effects of SGLT2 Inhibitors in Hemodialysis Patients: A Phase 2 Randomized Study

    Not yet reported Maximo Agustin Schiavone 80 participants Est. completion 2026-08 1 site Stand-alone
    Chronic kidney disease
    View official trial listing →
  • Recruiting NCT NCT06930092

    RestoratIon of Myocardial Function by PeRcutaneous cOronary interVEntion in Patients With Ischemic CardioMyoPathy

    Not yet reported Seoul National University Hospital 158 participants Est. completion 2029-04-30 1 site
    Other conditions: Ischemic Cardiomyopathy
    View official trial listing →
  • Recruiting NCT NCT06982079

    Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease

    Not yet reported Ain Shams University 60 participants Est. completion 2026-11-01 1 site Stand-alone
    Chronic kidney disease
    View official trial listing →
  • Recruiting NCT NCT07018622

    Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity

    Not yet reported Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran 46 participants Est. completion 2026-10-30 1 site Stand-alone
    Other conditions: Solid Tumors, Cisplatin Nephrotoxicity
    View official trial listing →
  • Recruiting NCT NCT07025629

    Dapagliflozin for Cardio-renal Protection After ICU Discharge

    Not yet reported Assistance Publique - Hôpitaux de Paris 600 participants Est. completion 2029-01-15 2 sites
    Heart failureChronic kidney disease
    View official trial listing →
  • Recruiting NCT NCT07056699

    SGLT2i, Pioglitazone, and Ketone Production in T1D

    Not yet reported The University of Texas Health Science Center at San Antonio 24 participants Est. completion 2027-06-30 1 site Stand-alone
    Other conditions: Type1diabetes
    View official trial listing →
  • Recruiting NCT NCT07082114

    A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus

    Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 800 participants Est. completion 2027-05-17 1 site
    Type 2 diabetes
    View official trial listing →
  • Recruiting NCT NCT07083388

    A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)

    Not yet reported Boryung Pharmaceutical Co., Ltd 52 participants Est. completion 2026-07-03 1 site Stand-alone
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Recruiting NCT NCT07157475

    Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors

    Wroclaw Medical University 300 participants Est. completion 2026-12-31 1 site
    Other conditions: Peripheral Arterial Disease(PAD)
    View official trial listing →
  • Recruiting NCT NCT07174687

    SGLT2 Inhibitors in Geographic Atrophy

    Not yet reported Washington University School of Medicine 70 participants Est. completion 2028-06 1 site Stand-alone
    Other conditions: Retinal Degeneration, Retinal Diseases, Eye Diseases, Geographic Atrophy, Pathological Conditions, Anatomical
    View official trial listing →
  • Recruiting NCT NCT07187570

    RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual Care

    Not yet reported Region Stockholm 1600 participants Est. completion 2027-12 7 sites Stand-alone
    Other conditions: Atrial Fibrillation (AF)
    View official trial listing →
  • Recruiting NCT NCT07231939

    Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI

    Collegium Medicum w Bydgoszczy 4000 participants Est. completion 2026-03-31 1 site
    Cardiovascular disease Other conditions: Acute Kidney Injury, Contrast-Induced Acute Kidney Injury, Percutaneous Coronary Intervention
    View official trial listing →
  • Recruiting NCT NCT07235280

    Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma

    Not yet reported Jonsson Comprehensive Cancer Center 48 participants Est. completion 2029-06-29 1 site Stand-alone
    Other conditions: Lung Adenocarcinoma, Stage IA1 Lung Cancer American Joint Committee on Cancer (AJCC) v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Lung Cancer
    View official trial listing →
  • Recruiting NCT NCT07239011

    Dapagliflozin in Depression

    Not yet reported, Not yet reported Tanta University 60 participants Est. completion 2026-12-20 1 site
    Other conditions: Depression
    View official trial listing →
  • Recruiting NCT NCT07239570

    A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease

    Not yet reported Peter Rossing 125 participants Est. completion 2028-06 4 sites Added to GLP-1
    Chronic kidney disease
    View official trial listing →
  • Recruiting NCT NCT07254572

    Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes

    Not yet reported National Institute of Cardiology, Warsaw, Poland 300 participants Est. completion 2029-08-01 1 site Stand-alone
    Cardiovascular diseasePrediabetes
    View official trial listing →
  • Recruiting NCT NCT07273838

    Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome

    Not yet reported Yale University 130 participants Est. completion 2029-10-31 2 sites Stand-alone
    Heart failure Other conditions: Acute Kidney Injury
    View official trial listing →
  • Recruiting NCT NCT07280585

    STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease

    Not yet reported University of Cologne 420 participants Est. completion 2030-05-15 30 sites Stand-alone
    Other conditions: Polycystic Kidney, Autosomal Dominant
    View official trial listing →
  • Recruiting NCT NCT07295223

    Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)

    Not yet reported Instituto Mexicano del Seguro Social 44 participants Est. completion 2026-09 1 site Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Recruiting NCT NCT07297589

    Epicardial Cardiac Fat-CT (EPIC-CT)

    Not yet reported Instituto Mexicano del Seguro Social 136 participants Est. completion 2027-03 1 site Stand-alone
    Cardiovascular disease Other conditions: Epicardial Fat
    View official trial listing →
  • Recruiting NCT NCT07335900

    A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis

    Not yet reported RenJi Hospital 25 participants Est. completion 2027-05-30 1 site Stand-alone
    Other conditions: Severe Aortic Valve Stenosis
    View official trial listing →
  • Recruiting NCT NCT07405216

    Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease

    Not yet reported Centenario Hospital Miguel Hidalgo 200 participants Est. completion 2027-10-30 1 site Stand-alone
    Chronic kidney disease Other conditions: Albuminuria, Adolescent, Sodium Glucose Co-Transporter 2 Inhibitors
    View official trial listing →
  • Recruiting NCT NCT07491042

    Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.

    Not yet reported Oman Ministry of Health 38 participants Est. completion 2027-01-31 1 site Stand-alone
    Other conditions: End Stage Chronic Renal Failure
    View official trial listing →
  • Recruiting NCT NCT07491718

    Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy

    Not yet reported University of Edinburgh 100 participants Est. completion 2028-08-09 1 site
    Other conditions: Takotsubo Cardiomyopathy
    View official trial listing →
  • Recruiting NCT NCT07513883

    The Assessment of Partial Guideline-Directed Medical Therapy Down Titration in Heart Failure in Remission.

    Not yet reported Ziekenhuis Oost-Limburg 100 participants Est. completion 2028-12 1 site
    Heart failure
    View official trial listing →
  • Recruiting NCT NCT07572032

    Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study

    Not yet reported Kyungsub Song 80 participants Est. completion 2028-12-20 4 sites Stand-alone
    Cardiovascular diseaseHeart failure Other conditions: Valvular Cardiomyopathy
    View official trial listing →
  • Recruiting NCT NCT07601867

    Effect of Dapagliflozin on Right Ventricular-Pulmonary Artery Coupling After Off-Pump Coronary Atery Bypass Grafting

    Pyatigorsk City Clinical Hospital Number 1 72 participants Est. completion 2028-07-01 1 site
    Heart failure Other conditions: Coronary Arterial Disease
    View official trial listing →
  • Recruiting NCT NCT07614230

    SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes

    Not yet reported Junjie Yang 144 participants Est. completion 2028-12-31 2 sites Stand-alone
    Type 2 diabetesCardiovascular disease Other conditions: Atherosclerosis
    View official trial listing →
  • Recruiting NCT NCT07631156

    STEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in Normalized Heart Failure

    Not yet reported Kyungsub Song 80 participants Est. completion 2029-12-30 5 sites Stand-alone
    Heart failure Other conditions: Ventricular Dysfunction, Left
    View official trial listing →
  • Recruiting NCT NCT07662044

    A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

    Not yet reported AstraZeneca 800 participants Est. completion 2028-07-14 149 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Recruiting NCT NCT07662109

    A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

    Not yet reported AstraZeneca 2000 participants Est. completion 2028-07-05 272 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Recruiting NCT NCT07684326

    "Exploring the Potential Benefits of Using Dapagliflozin in Cirrhotic Chronic Liver Disease Patients- A Randomized Controlled Trial"

    Not yet reported, Not yet reported Beni-Suef University 52 participants Est. completion 2027-09 1 site Stand-alone
    Other conditions: Ascites Hepatic
    View official trial listing →
  • Recruiting NCT NCT07754331

    Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapagliflozin

    Not yet reported AstraZeneca 10 participants Est. completion 2026-12-03 1 site
    Other conditions: Kidney Failure
    View official trial listing →
  • Recruiting NCT NCT07776054

    Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF

    Not yet reported Samsung Medical Center 200 participants Est. completion 2027-09-01 1 site Stand-alone
    Other conditions: Atrial Fibrillation, SGLT2 Inhibitor, DC Cardioversion
    View official trial listing →
  • Completed NCT NCT00162305

    A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects

    Not yet reported AstraZeneca 47 participants Est. completion 2005-08 5 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00357370

    A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes

    Not yet reported, Not yet reported AstraZeneca 163 participants Est. completion 2008-03 23 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00538174

    Phase I Multiple-Ascending Dose (Japan)

    Not yet reported AstraZeneca 36 participants Est. completion 2008-05 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00546741

    Drug Interaction With Metformin

    Not yet reported AstraZeneca 18 participants Est. completion 2008-02 1 site Stand-alone
    Other conditions: Healthy Male and Female Subjects
    View official trial listing →
  • Completed NCT NCT00562250

    Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects

    Not yet reported AstraZeneca 11 participants Est. completion 2008-08 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00660907

    Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients

    Not yet reported AstraZeneca 1217 participants Est. completion 2013-01 76 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00663260

    Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment

    Not yet reported, Not yet reported AstraZeneca 631 participants Est. completion 2011-06 96 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00680745

    Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients

    Not yet reported AstraZeneca 597 participants Est. completion 2010-05 66 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT00726505

    Renal Mechanism of Action/Splay vs. TmG

    Not yet reported AstraZeneca 1 participants Est. completion 2009-08 1 site
    Other conditions: Diabetes, NOS
    View official trial listing →
  • Completed NCT NCT00736879

    Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes

    Not yet reported AstraZeneca 497 participants Est. completion 2009-12-29 62 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00831779

    Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes

    Not yet reported AstraZeneca 116 participants Est. completion 2010-08 3 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00855166

    Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes

    Not yet reported AstraZeneca 182 participants Est. completion 2011-12 21 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00859898

    Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

    Not yet reported AstraZeneca 1093 participants Est. completion 2010-05 123 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00904176

    Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects

    Not yet reported AstraZeneca 30 participants Est. completion 2009-08 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00908271

    Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects

    Not yet reported AstraZeneca 7 participants Est. completion 2009-08 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00930865

    Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects

    Not yet reported AstraZeneca 42 participants Est. completion 2009-09 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00972244

    Trial to Evaluate the Efficacy and Safety of Dapagliflozin in Japanese Type 2 Diabetes Mellitus Patients

    Not yet reported AstraZeneca 417 participants Est. completion 2010-05 20 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00976495

    Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes

    Not yet reported AstraZeneca 154 participants Est. completion 2010-11 12 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00984867

    Dapagliflozin DPPIV Inhibitor add-on Study

    Not yet reported AstraZeneca 833 participants Est. completion 2011-09 88 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01002807

    Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State

    Not yet reported AstraZeneca 15 participants Est. completion 2010-01 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01031680

    Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension

    Not yet reported AstraZeneca 922 participants Est. completion 2012-12 140 sites Stand-alone
    Type 2 diabetesCardiovascular disease Other conditions: Hypertension, Inadequate Glycaemic Control
    View official trial listing →
  • Completed NCT NCT01055691

    A Study Comparing the Amount of Metformin and After Taking a Combination Tablet vs. Separate Tablets

    Not yet reported AstraZeneca 120 participants Est. completion 2010-04 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Terminated NCT NCT01068756

    Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects

    Not yet reported AstraZeneca 14 participants Est. completion 2010-04 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01095653

    A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

    Not yet reported AstraZeneca 1179 participants Est. completion 2012-03 39 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01095666

    A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

    Not yet reported AstraZeneca 1484 participants Est. completion 2013-03 33 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01135446

    Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects

    Not yet reported AstraZeneca 35 participants Est. completion 2010-06 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01137474

    A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker

    Not yet reported AstraZeneca 2996 participants Est. completion 2013-02 329 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01195662

    A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

    Not yet reported AstraZeneca 2245 participants Est. completion 2013-02 298 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01217892

    Evaluation of Dapagliflozin Taken Twice-daily

    Not yet reported AstraZeneca 400 participants Est. completion 2011-08 55 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Suspended NCT NCT01257412

    Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone

    Not yet reported AstraZeneca 375 participants Est. completion 2013-06 15 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01294423

    Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus

    Not yet reported AstraZeneca 261 participants Est. completion 2012-03 26 sites Stand-alone
    Type 2 diabetes Other conditions: High Blood Sugar
    View official trial listing →
  • Completed NCT NCT01294436

    Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus

    Not yet reported AstraZeneca 728 participants Est. completion 2012-09 38 sites Stand-alone
    Type 2 diabetes Other conditions: High Blood Sugar
    View official trial listing →
  • Completed NCT NCT01392677

    Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea

    Not yet reported AstraZeneca 311 participants Est. completion 2013-08 42 sites Stand-alone
    Type 2 diabetes Other conditions: High HbA1c Level, Inadequate Glycaemic Control
    View official trial listing →
  • Completed NCT NCT01525238

    PK Study of Dapagliflozin in Pediatric Subjects With T2DM

    Not yet reported AstraZeneca 53 participants Est. completion 2014-09-01 17 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01535677

    To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered Separately

    Not yet reported AstraZeneca 71 participants Est. completion 2013-07 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01619059

    Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

    Not yet reported AstraZeneca 315 participants Est. completion 2015-01 83 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01662999

    Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants

    Not yet reported AstraZeneca 42 participants Est. completion 2012-11 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01730534

    Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

    Not yet reported AstraZeneca 17190 participants Est. completion 2018-09-11 805 sites Stand-alone
    Other conditions: Diabetes Mellitus, Non-Insulin-Dependent, High Risk for Cardiovascular Event
    View official trial listing →
  • Terminated NCT NCT01944618

    forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)

    AstraZeneca 5000 participants Est. completion 2015-10 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02096705

    Phase III Insulin Add-On Asia Regional Program - ST

    Not yet reported AstraZeneca 477 participants Est. completion 2016-01-28 29 sites Stand-alone
    Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT02157298

    Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.

    Not yet reported AstraZeneca 266 participants Est. completion 2015-11 14 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02211742

    Dapagliflozin in Type 1 Diabetes

    Not yet reported Medical University Innsbruck 12 participants Est. completion 2017-02-08 1 site
    Other conditions: Fasting Glucose, Glucose Excursion, Glycemic Control
    View official trial listing →
  • Completed NCT NCT02223065

    Bioequivalence Study Coadministered to Healthy Subjects in the Fasted State

    Not yet reported AstraZeneca 36 participants Est. completion 2014-12 Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02229396

    Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

    Not yet reported AstraZeneca 695 participants Est. completion 2017-12-28 133 sites Added to GLP-1
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT02253121

    Glucose Control During Glucocorticoid Therapy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease

    Not yet reported Slotervaart Hospital 46 participants Est. completion 2017-05 4 sites Stand-alone
    Other conditions: Hyperglycemia Steroid-induced
    View official trial listing →
  • Completed NCT NCT02268214

    Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes

    Not yet reported AstraZeneca 833 participants Est. completion 2017-08-25 131 sites Stand-alone
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT02279407

    A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic Patients

    Not yet reported AstraZeneca 223 participants Est. completion 2015-12 5 sites Stand-alone
    Other conditions: T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)
    View official trial listing →
  • Completed NCT NCT02304081

    Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function

    Not yet reported Prof. Dr. Thomas Forst 64 participants Est. completion 2016-08 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02313220

    Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight

    Not yet reported Uppsala University 50 participants Est. completion 2016-03 1 site Added to GLP-1
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT02325206

    Phase 1 Study to Explore the Safety and Pharmacokinetics of DAPAglifozin in Adolescents and Adults With Type 1 Diabetes

    Not yet reported Kinderkrankenhaus auf der Bult 36 participants Est. completion 2015-12 1 site Stand-alone
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT02327039

    The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients

    Not yet reported University of Padova 33 participants Est. completion 2016-09 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02338193

    Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women

    Not yet reported Woman's 69 participants Est. completion 2019-03-13 1 site Stand-alone
    Other conditions: Diabetes Prevention in Women After GDM Who Are at High-risk
    View official trial listing →
  • Completed NCT NCT02338921

    Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy

    Not yet reported Seoul National University Bundang Hospital 78 participants Est. completion 2021-12-31 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT02372955

    Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes

    Not yet reported Gulf Regional Research & Educational Services, LLC 21 participants Est. completion 2016-12 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02383238

    Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content

    Not yet reported University of Erlangen-Nürnberg Medical School 59 participants Est. completion 2015-10 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02397421

    Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and Diabetes

    Not yet reported University of Dundee 56 participants Est. completion 2017-08 1 site
    Heart failure Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT02419612

    A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

    Not yet reported AstraZeneca 444 participants Est. completion 2019-09-18 84 sites Stand-alone
    Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT02426541

    Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus

    Not yet reported AstraZeneca 55 participants Est. completion 2016-04-28 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02433678

    An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin

    Not yet reported University at Buffalo 52 participants Est. completion 2018-11 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02459353

    Effect of Dapagliflozin on Glycemic Variability

    Not yet reported The Catholic University of Korea 86 participants Est. completion 2017-05 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02475070

    Vildagliptin Versus Dapagliflozin on Glucagon

    Not yet reported Lund University 28 participants Est. completion 2017-06 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02532855

    A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)

    Not yet reported Merck Sharp & Dohme LLC 614 participants Est. completion 2017-10-10 Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02547935

    A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

    Not yet reported, Not yet reported AstraZeneca 459 participants Est. completion 2018-05-18 112 sites Stand-alone
    Type 2 diabetesChronic kidney disease
    View official trial listing →
  • Completed NCT NCT02551874

    A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin

    Not yet reported AstraZeneca 650 participants Est. completion 2017-11-10 40 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT02558270

    Effects of SGLT-2 Inhibition on Hepatic Glucose and Energy Metabolism

    Not yet reported Medical University of Vienna 20 participants Est. completion 2018-06 1 site
    Type 2 diabetes Other conditions: Metabolically Healthy Controls
    View official trial listing →
  • Completed NCT NCT02561130

    Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga

    Not yet reported Population Health Research Institute 154 participants Est. completion 2018-12-31 7 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02582840

    The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM

    Not yet reported AstraZeneca 42 participants Est. completion 2016-06 1 site Stand-alone
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT02585804

    Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects

    Not yet reported University Health Network, Toronto 10 participants Est. completion 2017-04-24 1 site Stand-alone
    Other conditions: Focal Segmental Glomerulosclerosis
    View official trial listing →
  • Completed NCT NCT02597049

    A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus

    Not yet reported Eli Lilly and Company 424 participants Est. completion 2017-02 41 sites
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT02608905

    Effect of Dapagliflozin on Inflammation and Endothelial Function

    Not yet reported Baylor College of Medicine 17 participants Est. completion 2019-03 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02610088

    Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide

    Not yet reported Seoul National University Bundang Hospital 32 participants Est. completion 2018-09 1 site
    Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT02616666

    A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients

    Not yet reported University of Liverpool 632 participants Est. completion 2025-12-12 132 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02635386

    EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)

    Not yet reported Woman's 119 participants Est. completion 2020-10-09 1 site Stand-alone
    Other conditions: Polycystic Ovary Syndrome, Obesity
    View official trial listing →
  • Completed NCT NCT02636192

    Study on Incidence of Diabetic Ketoacidosis Among Participants With Type 2 Diabetes Mellitus Treated With Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors or Other Antihyperglycemic Agents

    Janssen Research & Development, LLC 200000 participants Est. completion 2017-04-07
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02653482

    Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure

    Not yet reported Saint Luke's Health System 263 participants Est. completion 2019-06-28 25 sites
    Heart failure
    View official trial listing →
  • Completed NCT NCT02681094

    A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

    Not yet reported AstraZeneca 905 participants Est. completion 2017-07-15 110 sites
    Type 2 diabetes Other conditions: Inadequate Glycaemic Control
    View official trial listing →
  • Completed NCT NCT02695095

    Acute Liver Injury in Patients on Dapagliflozin

    AstraZeneca 424091 participants Est. completion 2020-11-30 3 sites
    Other conditions: Acute Liver Injury
    View official trial listing →
  • Completed NCT NCT02695121

    Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment

    AstraZeneca 2133575 participants Est. completion 2025-01-30 4 sites
    Other conditions: Breast Cancer, Bladder Cancer
    View official trial listing →
  • Completed NCT NCT02695173

    Complications of UTI in Patients on Dapagliflozin

    AstraZeneca 683380 participants Est. completion 2020-11-30 3 sites
    Other conditions: Severe Complications of Urinary Tract Infections
    View official trial listing →
  • Completed NCT NCT02695810

    The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes

    Not yet reported Steno Diabetes Center Copenhagen 120 participants Est. completion 2019-01-13 1 site Stand-alone
    Other conditions: Prediabetic State, Obesity
    View official trial listing →
  • Withdrawn NCT NCT02719132

    Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActice

    Not yet reported AstraZeneca Est. completion 2017-11 Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02722239

    An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions

    Not yet reported AstraZeneca 40 participants Est. completion 2016-05-05 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02725593

    Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years

    Not yet reported AstraZeneca 72 participants Est. completion 2020-04-06 42 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02751398

    Impact of Dapagliflozin on DIAstolic Dysfunction in Type 2 Diabetic Patients

    Not yet reported Yonsei University 60 participants Est. completion 2020-06-15 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02777073

    Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes

    Not yet reported University at Buffalo 43 participants Est. completion 2016-12-31 1 site
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT02796170

    Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes

    Not yet reported Tulane University School of Medicine 11 participants Est. completion 2020-08 1 site
    Type 2 diabetes Other conditions: Hypertension
    View official trial listing →
  • Completed NCT NCT02805283

    Dapagliflozin Patient Satisfaction Survey

    AstraZeneca 653 participants Est. completion 2018-10-29 1 site
    Type 2 diabetes
    View official trial listing →
  • Withdrawn NCT NCT02811484

    Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes

    Not yet reported Weill Medical College of Cornell University Est. completion 2018-12 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT02879409

    HbA1c Variability in Type II Diabetes

    Not yet reported Weill Cornell Medical College in Qatar 150 participants Est. completion 2026-10-01 1 site Added to GLP-1
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT02887677

    Effects of Dapagliflozin on Central Hemodynamics and Urine Albumin Excretion in Patients With Type 2 Diabetes.

    Not yet reported Hellenic Society for Medical Education 85 participants Est. completion 2019-10 3 sites
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT02899949

    Health Outcomes of Patients With Type 2 Diabetes Treated With Dapagliflozin in Conjunction With Insulin

    London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's 212 participants Est. completion 2016-12
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02911792

    Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration

    Not yet reported The University of Texas Health Science Center at San Antonio 72 participants Est. completion 2023-07-11 2 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02914691

    Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes

    Not yet reported Peter Rossing 40 participants Est. completion 2017-07-05 1 site
    Type 2 diabetesChronic kidney disease
    View official trial listing →
  • Status unknown NCT NCT02919059

    Study to Asses the Effect of Dapagliflozin on Central Blood Pressure Reduction.

    Not yet reported IInstituto Gallego de Medicina Vascular 159 participants Est. completion 2019-08 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02925559

    Effect of Anti-diabetic Drugs on Glycemic Variability

    Not yet reported Centro de Diabetes Curitiba Ltda 135 participants Est. completion 2019-01 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02956811

    Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?

    Not yet reported University of Dundee 66 participants Est. completion 2019-04-02 1 site
    Type 2 diabetes Other conditions: Left Ventricular Hypertrophy
    View official trial listing →
  • Completed NCT NCT02966626

    A Real World Experience of Dapagliflozin in Type 2 Diabetes

    University of Malaya 223 participants Est. completion 2018-01
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02971618

    Study With Dapagliflozin

    AstraZeneca 929 participants Est. completion 2018-08-03 2 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02973477

    Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)

    Not yet reported University of Michigan 45 participants Est. completion 2019-08-22 1 site Stand-alone
    Type 2 diabetesCardiovascular disease
    View official trial listing →
  • Completed NCT NCT02981966

    Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects

    Not yet reported The University of Texas Health Science Center at San Antonio 32 participants Est. completion 2023-05-31 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02984644

    Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin

    Not yet reported The University of Texas Health Science Center at San Antonio 30 participants Est. completion 2019-11-16 1 site
    Other conditions: Type II; Diabetes
    View official trial listing →
  • Completed NCT NCT02987738

    Pilot Study to Explore the Efficacy of DAPAglifozin as add-on to Closed-loop Control in Patients With Type 1 Diabetes

    Not yet reported Kinderkrankenhaus auf der Bult 30 participants Est. completion 2017-12-19 1 site Stand-alone
    Other conditions: Type1diabetes
    View official trial listing →
  • Completed NCT NCT03030235

    Dapagliflozin in PRESERVED Ejection Fraction Heart Failure

    Not yet reported Saint Luke's Health System 324 participants Est. completion 2021-08-13 26 sites
    Heart failure
    View official trial listing →
  • Completed NCT NCT03036124

    Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure

    Not yet reported AstraZeneca 4744 participants Est. completion 2019-07-17 419 sites Stand-alone
    Heart failure
    View official trial listing →
  • Completed NCT NCT03038789

    XIGDUO Extended Release (XR) Post Marketing Surveillance

    AstraZeneca 623 participants Est. completion 2019-08-30 8 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03071016

    Usage of Dapagliflozin in the Management of Type-2 Diabetes Mellitus: A Real World Evidence Study in Indian Patients

    AstraZeneca 2000 participants Est. completion 2018-03-03 29 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03074630

    Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2)

    Not yet reported Amsterdam UMC, location VUmc 12 participants Est. completion 2018-04 1 site Stand-alone
    Type 2 diabetes Other conditions: Hypercholesterolemia
    View official trial listing →
  • Completed NCT NCT03089333

    Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects

    Not yet reported University of Campinas, Brazil 16 participants Est. completion 2017-12 1 site Stand-alone
    Type 2 diabetes Other conditions: Hypertension, Blood Pressure, Obesity, Cardiac Hypertrophy, Microalbuminuria, Vascular Stiffness
    View official trial listing →
  • Completed NCT NCT03138356

    Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects

    Not yet reported AstraZeneca 126 participants Est. completion 2017-11-28 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT03152084

    The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.

    Not yet reported AstraZeneca 24 participants Est. completion 2020-03-20 4 sites Stand-alone
    Type 2 diabetes Other conditions: Kidney Function Tests
    View official trial listing →
  • Completed NCT NCT03156985

    Multi-center, Single Arm, Observational Study to Evaluate the Safety of Dapagliflozin in Type 2 Diabetes Mellitus Patients in China

    AstraZeneca 3000 participants Est. completion 2021-01-27 83 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03168295

    PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria

    Not yet reported The University of Texas Health Science Center at San Antonio 34 participants Est. completion 2019-05-15 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03169959

    A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

    Not yet reported AstraZeneca 85 participants Est. completion 2017-08-03 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03180489

    Does Dapagliflozin Provide Additional Health Benefits To Dietary Counseling For Weight Loss?

    Not yet reported Christopher Bell 62 participants Est. completion 2018-12-21 1 site Stand-alone
    Other conditions: Weight Loss
    View official trial listing →
  • Completed NCT NCT03190694

    Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria

    Not yet reported Hiddo Lambers Heerspink 53 participants Est. completion 2019-12-01 7 sites Stand-alone
    Chronic kidney disease Other conditions: Proteinuria
    View official trial listing →
  • Completed NCT NCT03199053

    Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old

    Not yet reported AstraZeneca 256 participants Est. completion 2024-01-03 122 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03216278

    The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions

    Not yet reported AstraZeneca 284 participants Est. completion 2018-05-22 1 site Stand-alone
    Other conditions: Healthy Subjects in Fasted and Fed State
    View official trial listing →
  • Completed NCT NCT03269058

    Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes

    Not yet reported Centre Hospitalier Universitaire Dijon 28 participants Est. completion 2021-05-06 1 site Stand-alone
    Other conditions: Type-2 Diabetes, Oral Antidiabetics
    View official trial listing →
  • Completed NCT NCT03313752

    Effects of SGLT2 Inhibition on Myocardial Insulin Sensitivity

    Not yet reported Giaccari Andrea 25 participants Est. completion 2022-10-06 1 site Stand-alone
    Type 2 diabetesCardiovascular disease
    View official trial listing →
  • Completed NCT NCT03316131

    A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA

    Not yet reported AstraZeneca 36 participants Est. completion 2018-07-19 2 sites Stand-alone
    Other conditions: Asymptomatic Hyperuricemia
    View official trial listing →
  • Completed NCT NCT03331289

    Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria

    Not yet reported The University of Texas Health Science Center at San Antonio 107 participants Est. completion 2022-11-04 1 site
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT03344341

    A Phase IV Study in Drug-Naive Patients With T2DM in China

    Not yet reported AstraZeneca 304 participants Est. completion 2019-05-24 20 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03361098

    DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2

    Not yet reported Amsterdam UMC, location VUmc 65 participants Est. completion 2020-03-25 1 site Added to GLP-1
    Type 2 diabetes Other conditions: Obesity
    View official trial listing →
  • Status unknown NCT NCT03377335

    Dapagliflozin, Cardio-Metabolic Risk Factors and Type-2 Diabetes

    Not yet reported University of Palermo 186 participants Est. completion 2019-01 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03387683

    A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes Patients

    Not yet reported AstraZeneca 53 participants Est. completion 2019-03-19 2 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT03398577

    Effects of SGLT2 Inhibitor in Diabetic Patients With Coronary Artery Disease

    Not yet reported Sheba Medical Center 61 participants Est. completion 2018-12-31 1 site Stand-alone
    Other conditions: Coronary Disease With Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT03407196

    Dapagliflozin in Type 2 Diabetes Patients, a Retrospective Cohort Study From Turkey

    AstraZeneca Turkey 1683 participants Est. completion 2018-02-28 1 site
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT03419624

    The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients

    Not yet reported Universitätsklinikum Hamburg-Eppendorf 13 participants Est. completion 2019-08-05 4 sites Added to GLP-1
    Type 2 diabetes Other conditions: Obesity
    View official trial listing →
  • Withdrawn NCT NCT03423355

    Dapagliflozin Effect on Erythropoiesis and Physical Fitness

    Not yet reported University Hospital Tuebingen Est. completion 2023-12 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03444584

    Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes

    Not yet reported MedImmune LLC 49 participants Est. completion 2018-12-06 8 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03492580

    A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

    Janssen Research & Development, LLC 714582 participants Est. completion 2018-06-25 1 site
    Type 2 diabetesCardiovascular disease
    View official trial listing →
  • Completed NCT NCT03499704

    A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy

    Not yet reported Celltrion Pharm, Inc. 133 participants Est. completion 2024-01-16 15 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03556033

    Effect of Dapagliflozin on IAH in T1DM

    Not yet reported Radboud University Medical Center 15 participants Est. completion 2019-12-20 1 site
    Other conditions: Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemia Unawareness
    View official trial listing →
  • Status unknown NCT NCT03565458

    Gemigliptin, Dapagliflozin, Empagliflozin DDI Study

    Not yet reported LG Chem 48 participants Est. completion 2018-12-22 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT03608358

    Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin

    Not yet reported AstraZeneca 41 participants Est. completion 2020-08-04 4 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03619213

    Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

    Not yet reported AstraZeneca 6263 participants Est. completion 2022-03-27 348 sites Stand-alone
    Heart failure
    View official trial listing →
  • Completed NCT NCT03624803

    DAPA - Egypt Study

    AstraZeneca 200 participants Est. completion 2020-03-30 21 sites
    Other conditions: Type-2 Diabetes
    View official trial listing →
  • Status unknown NCT NCT03658031

    Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction

    Not yet reported Hamad Medical Corporation 576 participants Est. completion 2021-01-31 1 site Stand-alone
    PrediabetesCardiovascular diseaseType 2 diabetes Other conditions: CVD
    View official trial listing →
  • Completed NCT NCT03704818

    Dapagliflozin Effects on Hypoglycemia

    Not yet reported University of California, San Diego 22 participants Est. completion 2021-11-30 1 site Stand-alone
    Other conditions: Type1 Diabetes Mellitus
    View official trial listing →
  • Status unknown NCT NCT03710460

    Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in Obesity

    Not yet reported University of Guadalajara 33 participants Est. completion 2023-12-30 1 site Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT03714594

    Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.

    Not yet reported University of Pisa 48 participants Est. completion 2022-08-31 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03723252

    Dapagliflozin Efficacy and Action in NASH

    Not yet reported Nanfang Hospital, Southern Medical University 154 participants Est. completion 2024-03-28 1 site Stand-alone
    MASH
    View official trial listing →
  • Completed NCT NCT03748810

    Head-to-head Comparison of Empagliflozin and Dapagliflozin

    Chungbuk National University Hospital 600 participants Est. completion 2022-06-30 1 site
    Type 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT03762850

    A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

    Not yet reported Travere Therapeutics, Inc. 406 participants Est. completion 2026-07 162 sites Stand-alone
    Other conditions: Immunoglobulin A Nephropathy
    View official trial listing →
  • Completed NCT NCT03766724

    Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults

    Not yet reported Dong-A ST Co., Ltd. 42 participants Est. completion 2019-01-18 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Withdrawn NCT NCT03766750

    Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus.

    Not yet reported EMS Est. completion 2023-11
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03782259

    Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2

    Not yet reported University of Washington 62 participants Est. completion 2022-11-16 1 site
    Type 2 diabetes Other conditions: Myocardial Fibrosis, Myocardial Inflammation
    View official trial listing →
  • Status unknown NCT NCT03794518

    Effect of Dapagliflozin Plus Low Dose Pioglitazone on Hospitalization Rate in Patients With HF and HFpEF

    Not yet reported Hamad Medical Corporation 648 participants Est. completion 2021-12 1 site
    Other conditions: Risk Reduction
    View official trial listing →
  • Status unknown NCT NCT03804411

    Prognostic Predictors of Response to Hypoglycemic Therapy

    Not yet reported Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health 800 participants Est. completion 2020-05 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03826641

    A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1801 in Healthy Subjects

    Not yet reported Hanmi Pharmaceutical Company Limited 85 participants Est. completion 2019-04-16 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT03877224

    DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction

    Not yet reported AstraZeneca 504 participants Est. completion 2020-07-09 101 sites Stand-alone
    Heart failure
    View official trial listing →
  • Completed NCT NCT03877237

    DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction

    Not yet reported AstraZeneca 313 participants Est. completion 2020-03-07 76 sites Stand-alone
    Heart failure
    View official trial listing →
  • Active, not recruiting NCT NCT03878459

    Dapagliflozin Plus Pioglitazone in T1DM

    Not yet reported The University of Texas Health Science Center at San Antonio 120 participants Est. completion 2027-12-31 3 sites
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Active, not recruiting NCT NCT03899402

    Triple Therapy in T1DM

    Not yet reported, Not yet reported State University of New York at Buffalo 78 participants Est. completion 2026-06-30 1 site Added to GLP-1
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT03918148

    Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)

    University of Campania Luigi Vanvitelli 1150 participants Est. completion 2023-12-31 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03939624

    Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events

    Canadian Network for Observational Drug Effect Studies, CNODES 419734 participants Est. completion 2019-10-01 1 site
    Type 2 diabetesCardiovascular diseaseHeart failure Other conditions: Cardiovascular Death, All-Cause Mortality
    View official trial listing →
  • Completed NCT NCT03959501

    Metabolic Responses of Dapagliflozin vs Sitagliptin in T2DM Patients Inadequately Controlled With Insulin Therapy

    Not yet reported The University of Hong Kong 60 participants Est. completion 2020-10-16 1 site Stand-alone
    Type 2 diabetes Other conditions: Ketonemia
    View official trial listing →
  • Status unknown NCT NCT03961659

    Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese T2DM Patients Controlled Inadequately With Metformin Monotherapy.

    Not yet reported The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 87 participants Est. completion 2021-02 1 site
    Type 2 diabetes Other conditions: Obesity, Cognitive Impairment
    View official trial listing →
  • Completed NCT NCT03968224

    Effectiveness of Dapagliflozin for Weight Loss

    Not yet reported, Not yet reported Centro Medico Nacional Siglo XXI IMSS 160 participants Est. completion 2024-07-31 1 site Stand-alone
    PrediabetesType 2 diabetes Other conditions: Obesity, Morbid
    View official trial listing →
  • Status unknown NCT NCT04014192

    Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus

    Not yet reported Peking Union Medical College Hospital 40 participants Est. completion 2020-07-31 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04035031

    Effects of Dapagliflozin on Hormonal Glucose Homeostasis in Type 1 Diabetes

    Not yet reported Insel Gruppe AG, University Hospital Bern 13 participants Est. completion 2020-11-12 1 site Stand-alone
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT04049110

    Dapagliflozin in Physical Exercise in Type 1 Diabetes

    Not yet reported Insel Gruppe AG, University Hospital Bern 39 participants Est. completion 2023-05-10 1 site Stand-alone
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT04090580

    Impact on Glycemic Variability in Newly Onset T2DM Patients Initiating Dapagliflozin Plus Metformin Versus Metformin Alone

    Not yet reported Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran 88 participants Est. completion 2021-03-30 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT04120623

    Therapeutic Effect of Dapagliflozin Combined With CSII on Newly Diagnosed Type 2 Diabetes Mellitus

    Not yet reported Nanjing First Hospital, Nanjing Medical University 100 participants Est. completion 2020-02-28 Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04170543

    A Phase 2b Diabetic Kidney Disease Study

    Not yet reported AstraZeneca 609 participants Est. completion 2023-05-16 97 sites Stand-alone
    Chronic kidney disease
    View official trial listing →
  • Completed NCT NCT04170998

    Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

    Not yet reported Dong-A ST Co., Ltd. 283 participants Est. completion 2021-12-08 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04184947

    Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists

    University of Padova 10000 participants Est. completion 2020-02-29 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04193566

    Acute Effects of SGLT2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes

    Not yet reported Steno Diabetes Center Copenhagen 30 participants Est. completion 2021-01-01 1 site
    Other conditions: Nephropathy, Hypoxia, Mitochondrial Alteration, Type 1 Diabetes, Autonomic Neuropathy, Diabetic
    View official trial listing →
  • Status unknown NCT NCT04195243

    Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus

    Not yet reported Centro Universitario de Ciencias de la Salud, Mexico 24 participants Est. completion 2020-12-30 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04196231

    Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)

    Not yet reported University of Campania Luigi Vanvitelli 258 participants Est. completion 2020-10-20 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04197635

    Short-term Effects of Dapagliflozin on Peak VO2 in HFrEF

    Not yet reported Fundación para la Investigación del Hospital Clínico de Valencia 74 participants Est. completion 2022-04-19 1 site
    Heart failure
    View official trial listing →
  • Status unknown NCT NCT04200586

    The Effects of SGLTi on Diabetic Cardiomyopathy

    Not yet reported The University of Hong Kong 30 participants Est. completion 2021-09-30 1 site Stand-alone
    Type 2 diabetesHeart failure
    View official trial listing →
  • Completed NCT NCT04213677

    Dapagliflozin Efficacy and Action in PCOS

    Not yet reported Nanfang Hospital, Southern Medical University 165 participants Est. completion 2022-11-01 1 site Stand-alone
    Other conditions: Polycystic Ovary Syndrome
    View official trial listing →
  • Completed NCT NCT04215523

    Replication of the DECLARE Diabetes Trial in Healthcare Claims

    Brigham and Women's Hospital 49790 participants Est. completion 2021-02-18 1 site
    Other conditions: Diabetes
    View official trial listing →
  • Terminated NCT NCT04234867

    Study to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D)

    Not yet reported Kinderkrankenhaus auf der Bult 2 participants Est. completion 2022-08-26 1 site Stand-alone
    Other conditions: Type 1 Diabetes, Diabetic Ketoacidosis
    View official trial listing →
  • Status unknown NCT NCT04242758

    Phthalates Exposure in Type 2 Diabetic Patients and Diuretic Therapy

    Not yet reported University of Pisa 30 participants Est. completion 2020-04-01 1 site Stand-alone
    Other conditions: Renal Function Disorder, Glucose Metabolism Disorders
    View official trial listing →
  • Completed NCT NCT04249778

    Dapagliflozin at Discharge on Hospital Heart Failure Readmission

    Not yet reported Emory University 105 participants Est. completion 2022-03-03 3 sites Stand-alone
    Heart failure Other conditions: Diabetes
    View official trial listing →
  • Status unknown NCT NCT04255238

    A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone

    Not yet reported LG Chem 468 participants Est. completion 2022-12-30 Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT04258371

    DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk

    Not yet reported University Health Network, Toronto 50 participants Est. completion 2023-12 1 site Stand-alone
    Other conditions: Cardiovascular Risk Factor
    View official trial listing →
  • Status unknown NCT NCT04287387

    Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents

    Not yet reported Peking Union Medical College Hospital 180 participants Est. completion 2021-03-02 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04298229

    Efficacy and Safety of Dapagliflozin in Acute Heart Failure

    Not yet reported Vanderbilt University Medical Center 240 participants Est. completion 2023-05-17 6 sites Stand-alone
    Heart failureType 2 diabetes
    View official trial listing →
  • Completed NCT NCT04304430

    Comparative Effectiveness of Dapagliflozin Versus DPP-4 Inhibitors

    University of Padova 11206 participants Est. completion 2020-02-29 1 site
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT04330079

    Effects of dapaglifloziN Therapy on Myocardial Perfusion Reserve in Prediabetic Patients With Stable coronarY Artery Disease

    Not yet reported CHEOL WHAN LEE, M.D., Ph.D 2 participants Est. completion 2021-04-08 1 site Stand-alone
    Cardiovascular disease Other conditions: Prediabetic State
    View official trial listing →
  • Status unknown NCT NCT04340908

    Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac Surgery

    Not yet reported Hongchang Guo 500 participants Est. completion 2023-06-01 1 site Stand-alone
    Type 2 diabetes Other conditions: Cardiac Surgery
    View official trial listing →
  • Completed NCT NCT04350593

    Dapagliflozin in Respiratory Failure in Patients With COVID-19

    Not yet reported Saint Luke's Health System 1250 participants Est. completion 2021-06-11 95 sites
    Other conditions: COVID-19
    View official trial listing →
  • Completed NCT NCT04356742

    Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

    Not yet reported Dong-A ST Co., Ltd. 198 participants Est. completion 2022-02-23 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04363697

    Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)

    Not yet reported The TIMI Study Group 2401 participants Est. completion 2025-06-02 1 site Stand-alone
    Heart failure
    View official trial listing →
  • Completed NCT NCT04385589

    Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure

    Not yet reported Assiut University 100 participants Est. completion 2020-12-20 1 site
    Heart failure
    View official trial listing →
  • Completed NCT NCT04393246

    mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms

    Not yet reported, Not yet reported Cambridge University Hospitals NHS Foundation Trust 454 participants Est. completion 2022-06-08 1 site Stand-alone
    Other conditions: COVID-19
    View official trial listing →
  • Completed NCT NCT04445714

    To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus Patients

    Not yet reported AstraZeneca 196 participants Est. completion 2023-03-14 9 sites
    Type 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT04451837

    Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology

    Not yet reported Region Skane 200 participants Est. completion 2026-12-31 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04473417

    Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects

    Not yet reported Dong-A ST Co., Ltd. 60 participants Est. completion 2020-10-12 1 site
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT04505774

    Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

    Not yet reported Matthew Neal MD 3591 participants Est. completion 2024-01-26 101 sites
    Other conditions: Covid19
    View official trial listing →
  • Withdrawn NCT NCT04531397

    Efficacy and Safety of Dapagliflozin in Children With Proteinuric Chronic Kidney Disease

    Not yet reported Children's Hospital of Fudan University Est. completion 2022-12-31 1 site Stand-alone
    Chronic kidney disease Other conditions: Proteinuria
    View official trial listing →
  • Completed NCT NCT04534270

    Efficacy and Safety of Dapagliflozin in Children With Proteinuria

    Not yet reported Children's Hospital of Fudan University 23 participants Est. completion 2022-03-30 1 site Stand-alone
    Other conditions: Proteinuria
    View official trial listing →
  • Status unknown NCT NCT04544319

    Clinical Trial to Compare the PK of the Fixed-dose Combinations and Each Component of Gemigliptin/Dapagliflozin 50/10 mg

    Not yet reported LG Chem 44 participants Est. completion 2021-07 Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04545411

    Combination GRA and SGLT-2i Treatment in Type 1 Diabetes

    Not yet reported, Not yet reported University of California, San Diego 12 participants Est. completion 2022-10-31 1 site
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT04564742

    Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.

    Not yet reported AstraZeneca 4017 participants Est. completion 2023-07-05 103 sites Stand-alone
    Cardiovascular diseaseHeart failure
    View official trial listing →
  • Status unknown NCT NCT04570865

    Dapagliflozin And Pulmonary Artery Hemodynamics in Heart Failure With Reduced Ejection Fraction Patients With CardioMEMS®

    Not yet reported Scripps Health 100 participants Est. completion 2022-02-01 1 site Stand-alone
    Heart failure
    View official trial listing →
  • Completed NCT NCT04575675

    Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy

    Not yet reported Cheng-Hsin General Hospital 78 participants Est. completion 2020-12-30 1 site Stand-alone
    Heart failure Other conditions: Hypotension
    View official trial listing →
  • Completed NCT NCT04634500

    The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.

    Not yet reported Daewoong Pharmaceutical Co. LTD. 200 participants Est. completion 2021-11-03 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Withdrawn NCT NCT04640493

    SGLT2-Inhibitors for Sleep Apnea in Heart Failure

    Not yet reported Columbia University Est. completion 2025-08 1 site Stand-alone
    Heart failure Other conditions: Sleep Disordered Breathing
    View official trial listing →
  • Completed NCT NCT04654390

    The Efficacy Nad Safety of DWP16001 Compared to Active Drug in the Treatment of Type 2 Diabetes Mellitus

    Not yet reported Daewoong Pharmaceutical Co. LTD. 270 participants Est. completion 2021-12-17 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT04706637

    A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin

    Not yet reported Kyung Hee University Hospital at Gangdong 120 participants Est. completion 2023-01-31 7 sites
    Type 2 diabetes Other conditions: Bone Diseases, Metabolic
    View official trial listing →
  • Status unknown NCT NCT04707261

    Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)

    Not yet reported Xiangtan Central Hospital 1990 participants Est. completion 2026-01-01 1 site Stand-alone
    Heart failure Other conditions: Anemia
    View official trial listing →
  • Completed NCT NCT04707352

    Impact on Atrial Remodeling of Dapaglifozin in Patients With Heart Failure .

    Not yet reported Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia 162 participants Est. completion 2023-03-26 1 site Stand-alone
    Heart failure
    View official trial listing →
  • Completed NCT NCT04717986

    Dapagliflozin Effects on Mayor Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction (DAPA-AMI)

    Not yet reported Instituto Mexicano del Seguro Social 188 participants Est. completion 2023-06-20 1 site Stand-alone
    Cardiovascular diseaseHeart failure Other conditions: Cardiovascular Morbidity, Angina, Unstable
    View official trial listing →
  • Completed NCT NCT04735042

    SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.

    University of Pisa 60 participants Est. completion 2022-04-07 1 site
    Type 2 diabetes Other conditions: Urinary Tract Infections
    View official trial listing →
  • Status unknown NCT NCT04739215

    Effects of SGLT2 Inhibition on the Mechanisms of Cardiac Damage in the Diabetic Patient With HFpEF

    Not yet reported Hospital General Universitario Gregorio Marañon 62 participants Est. completion 2022-12-30 1 site Stand-alone
    Type 2 diabetesHeart failure
    View official trial listing →
  • Completed NCT NCT04743453

    EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS.

    Not yet reported University of Sao Paulo General Hospital 211 participants Est. completion 2024-09-02 1 site Stand-alone
    Type 2 diabetes Other conditions: Kidney Transplantation, Diabetes Complications
    View official trial listing →
  • Completed NCT NCT04778787

    Sodium-glucose Cotransporter Type 2 Inhibitors for Acute Cardiorenal Syndrome Prevention

    Not yet reported I.M. Sechenov First Moscow State Medical University 370 participants Est. completion 2022-08-01 2 sites Stand-alone
    Heart failure
    View official trial listing →
  • Status unknown NCT NCT04783870

    Effect of Dapagliflozin on LV Remodeling Post AMI

    Not yet reported Instituto Mexicano del Seguro Social 60 participants Est. completion 2024-12-31 1 site Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT04794517

    Dapagliflozin in Non-diabetic Stage IV CKD

    Not yet reported Mario Negri Institute for Pharmacological Research 32 participants Est. completion 2024-05-07 1 site Stand-alone
    Chronic kidney disease
    View official trial listing →
  • Status unknown NCT NCT04796428

    GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial

    Not yet reported Center for Outcomes Research and Clinical Epidemiology, Italy 1167 participants Est. completion 2023-12-31
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04798222

    Study to Assess the Bioavailability of Different Formulations of AZD9977 and Dapagliflozin and Influence of Food in Selected Formulations in Healthy Volunteers

    Not yet reported AstraZeneca 20 participants Est. completion 2021-09-03 1 site Stand-alone
    Heart failure
    View official trial listing →
  • Status unknown NCT NCT04806633

    Dapagliflozin to Prevent the Incidence of Contrast Induced Nephropathy After Heart Catheterization and Percutaneous Coronary Intervention

    Not yet reported G.Gennimatas General Hospital 1722 participants Est. completion 2023-12-01 2 sites
    Other conditions: Left Cardiac Catheterization, Percutaneous Coronary Intervention, Acute Kidney Injury, Sodium-glucose Co-transporter 2 Inhibitors
    View official trial listing →
  • Completed NCT NCT04818034

    The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study

    Not yet reported University of California, San Francisco 10 participants Est. completion 2022-04-28 1 site Stand-alone
    Other conditions: Cystinuria
    View official trial listing →
  • Completed NCT NCT04856969

    Clinical Trial to Evaluate Pharmacokinetic Interaction of ATB-1011 and ATB-1012 in Healthy Adult Volunteers

    Not yet reported Autotelicbio 38 participants Est. completion 2021-05-04 1 site
    Other conditions: Healthy Adult Volunteers
    View official trial listing →
  • Status unknown NCT NCT04860011

    DAPAgliflozin Versus Thiazide Diuretic in Patients With Heart Failure and Diuretic RESISTance

    Not yet reported NHS Greater Glasgow and Clyde 61 participants Est. completion 2023-04-03 2 sites Stand-alone
    Heart failure
    View official trial listing →
  • Completed NCT NCT04869124

    Dapagliflozin on Volume Vascular Outcomes.

    Not yet reported Frank Ruschitzka 80 participants Est. completion 2024-10-28 1 site
    Heart failure
    View official trial listing →
  • Completed NCT NCT04880993

    Bioequivalence of Dapagliflozin 10 mg Tablets Under Fasting Conditions

    Not yet reported Jiangsu Hansoh Pharmaceutical Co., Ltd. 30 participants Est. completion 2021-02-04 1 site Stand-alone
    Other conditions: Healthy Subjects
    View official trial listing →
  • Completed NCT NCT04881006

    Bioequivalence of Dapagliflozin 10 mg Tablets Under Fed Conditions

    Not yet reported Jiangsu Hansoh Pharmaceutical Co., Ltd. 30 participants Est. completion 2021-01-15 1 site Stand-alone
    Other conditions: Healthy Subjects
    View official trial listing →
  • Completed NCT NCT04882813

    Replication of the DAPA-CKD (Chronic Kidney Disease) Trial in Healthcare Claims Data

    Brigham and Women's Hospital 87727 participants Est. completion 2021-06-11 1 site
    Chronic kidney disease
    View official trial listing →
  • Completed NCT NCT04923295

    The Effect of Dapagliflozin on Ultrafiltration Among Peritoneal Dialysis Patients

    Not yet reported An-Najah National University 20 participants Est. completion 2021-07-28 1 site Stand-alone
    Other conditions: Peritoneal Dialysis Complication, Ultrafiltration Failure
    View official trial listing →
  • Completed NCT NCT04930549

    Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC)

    Not yet reported University Hospital, Rouen 32 participants Est. completion 2024-09-23 2 sites Stand-alone
    Other conditions: Renal Insufficiency, Chronic
    View official trial listing →
  • Completed NCT NCT04956263

    A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes

    Not yet reported Youngene Therapeutics Inc., Ltd. 19 participants Est. completion 2022-07-19 1 site
    Other conditions: Diabetes, Diabetes Mellitus, Type 1, Type1diabetes, Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT04965935

    Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients

    Not yet reported University Health Network, Toronto 52 participants Est. completion 2024-08-30 1 site Stand-alone
    Type 2 diabetes Other conditions: Kidney Transplant Recipients, Post-transplant Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT04972539

    Evaluation of Pharmacokinetics and Safety of AJU-A51 in Healthy Adults

    Not yet reported AJU Pharm Co., Ltd. 48 participants Est. completion 2021-03-09 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04991571

    Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants

    Not yet reported AstraZeneca 27 participants Est. completion 2021-10-22 1 site Stand-alone
    Chronic kidney disease
    View official trial listing →
  • Status unknown NCT NCT05014594

    Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT

    Not yet reported Post Graduate Institute of Medical Education and Research, Chandigarh 44 participants Est. completion 2022-05-19 1 site
    Other conditions: Cirrhosis, Ascites Hepatic
    View official trial listing →
  • Completed NCT NCT05017987

    Clinical Trial to Compare Pharmacokinetics After Administration of ATB-101 or Co-administration of ATB-1011 and ATB-1012

    Not yet reported Autotelicbio 36 participants Est. completion 2021-07-12 1 site
    Other conditions: Healthy Adult Volunteers
    View official trial listing →
  • Completed NCT NCT05042505

    Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation

    Not yet reported Medanta, The Medicity, India 100 participants Est. completion 2026-02-27 1 site
    Other conditions: Diabetes Mellitus, Liver Transplant; Complications
    View official trial listing →
  • Status unknown NCT NCT05045274

    The Effect of Early Administration of Dapagliflozin in STEMI Patients With LV Systolic Dysfunction

    Not yet reported Assiut University 300 participants Est. completion 2022-09
    Cardiovascular disease Other conditions: Left Ventricular Systolic Dysfunction
    View official trial listing →
  • Completed NCT NCT05050500

    Effects of Dapagliflozin on Inflammatory Factorslevel and Prognosis in Type 2 Diabetes With Acute Myocardial Infarction

    Not yet reported Qingdao Central Hospital 143 participants Est. completion 2024-12-30 1 site Stand-alone
    Cardiovascular disease Other conditions: Diabete Type 2, Glucose Intolerance
    View official trial listing →
  • Status unknown NCT NCT05101135

    To Evaluate the Efficacy and Safety of JT-001 add-on in Paatients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

    Not yet reported Jeil Pharmaceutical Co., Ltd. 256 participants Est. completion 2022-10-31 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT05105698

    Food-effect Bioavailability of Gemigliptin and Dapagliflozin 50/10 mg

    Not yet reported LG Chem 28 participants Est. completion 2022-09-30 Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Terminated NCT NCT05139914

    Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes

    Not yet reported Boston University 4 participants Est. completion 2025-02-04 1 site Stand-alone
    Type 2 diabetes Other conditions: Endothelial Dysfunction
    View official trial listing →
  • Status unknown NCT NCT05159882

    Safety and Efficacy of THR-1442 Compared to Dapagliflozin as Add-on Therapy to Metformin in T2DM

    Not yet reported Newsoara Biopharma Co., Ltd. 390 participants Est. completion 2022-09-30 6 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT05160974

    QTERN (SAXAGLIPTIN/DAPAGLIFLOZIN FDC) Regulatory Post-Marketing Surveillance

    AstraZeneca 679 participants Est. completion 2024-04-01 34 sites
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT05161429

    BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

    Brigham and Women's Hospital 550000 participants Est. completion 2024-06-30 5 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT05179356

    Dapagliflozin in Pulmonary Arterial Hypertension

    Not yet reported Mads Ersbøll 52 participants Est. completion 2026-01-13 1 site
    Other conditions: Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
    View official trial listing →
  • Completed NCT NCT05179668

    SGLT2 Inhibition in Hemodialysis

    Not yet reported Medical University of Vienna 220 participants Est. completion 2026-02-28 9 sites Stand-alone
    Type 2 diabetesChronic kidney disease Other conditions: Kidney Failure, Hemodialysis, Left Ventricular Hypertrophy
    View official trial listing →
  • Completed NCT NCT05188144

    Real-world Dapagliflozin Experience in Patients With Heart Failure in United Kingdom.

    AstraZeneca 237 participants Est. completion 2024-03-02 10 sites
    Heart failure
    View official trial listing →
  • Status unknown NCT NCT05194592

    Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 Diabetes

    Not yet reported Wonju Severance Christian Hospital 122 participants Est. completion 2025-06-30 1 site
    Type 2 diabetes Other conditions: Remodeling, Ventricular
    View official trial listing →
  • Completed NCT NCT05196347

    Dapagliflozin and Renal Surrogate Outcomes in Advanced Chronic Kidney Disease

    Not yet reported Kaohsiung Medical University 180 participants Est. completion 2024-08-31 1 site Stand-alone
    Chronic kidney disease
    View official trial listing →
  • Active, not recruiting NCT NCT05220917

    Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

    Brigham and Women's Hospital 781430 participants Est. completion 2027-09-30 1 site
    Type 2 diabetes Other conditions: Cardiovascular Events, Renal Disease
    View official trial listing →
  • Status unknown NCT NCT05226897

    Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients

    Not yet reported Yooyoung Pharmaceutical Co., Ltd. 256 participants Est. completion 2023-06-26 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT05236998

    A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers

    Not yet reported SK Chemicals Co., Ltd. 45 participants Est. completion 2021-12-31 1 site Stand-alone
    Other conditions: Healthy Subjects
    View official trial listing →
  • Status unknown NCT NCT05241431

    Effect of Dapagliflozin on Myocardial and Renal Function Following Aortic Valve Stenosis Intervention

    Not yet reported, Not yet reported University of Aarhus 106 participants Est. completion 2024-04-01 1 site
    Other conditions: Aortic Stenosis, Left Ventricle Hypertrophied
    View official trial listing →
  • Completed NCT NCT05250011

    Observation of Italian Patients With Heart Failure Being Treated With Dapagliflozin in Clinical Practice

    AstraZeneca 252 participants Est. completion 2024-04-15 11 sites
    Heart failure
    View official trial listing →
  • Status unknown NCT NCT05250752

    Reduction of Peritoneal Glucose Uptake With Use of SGLT2 in Humans Undergoing Peritoneal Dialysis Treatment

    Not yet reported Holbaek Sygehus 10 participants Est. completion 2022-12-31 1 site
    Other conditions: End Stage Renal Disease, Peritoneal Dialysis Complication
    View official trial listing →
  • Terminated NCT NCT05268926

    TreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertension

    Not yet reported University Medical Center Groningen 9 participants Est. completion 2023-02-02 1 site
    Other conditions: Albuminuria
    View official trial listing →
  • Completed NCT NCT05278962

    HF Patients With LVADs Being Treated With SGLT2i

    Not yet reported University of Chicago 32 participants Est. completion 2025-08-31 1 site
    Heart failure
    View official trial listing →
  • Status unknown NCT NCT05296044

    To Evaluate the Efficacy and Safety of JT-003 add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

    Not yet reported Jeil Pharmaceutical Co., Ltd. 245 participants Est. completion 2024-02-28 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT05308160

    A Single Center, Randomized, Open Label, Parallel Group, Phase 3 Study to Evaluate the Efficacy of Dapagliflozin in Subjects With Nonalcoholic Fatty Liver Disease

    Not yet reported National Taiwan University Hospital 75 participants Est. completion 2024-04-30 1 site
    Other conditions: Fatty Liver
    View official trial listing →
  • Status unknown NCT NCT05310916

    Effect of SGLT2i on Diabetic Retinopathy in Type 2 Diabetes Mellitus Patients

    Not yet reported Nidae Alaa 60 participants Est. completion 2023-11 1 site Stand-alone
    Other conditions: Diabetic Retinopathy
    View official trial listing →
  • Active, not recruiting NCT NCT05321706

    DAPAgliflozin for Renal Protection in Heart Transplant Recipients

    Not yet reported Oslo University Hospital 430 participants Est. completion 2028-11-30 6 sites
    Other conditions: Heart Transplant Failure, Kidney Failure
    View official trial listing →
  • Withdrawn NCT NCT05330013

    The Effect of Inflammation in Heart Failure

    Not yet reported National Heart, Lung, and Blood Institute (NHLBI) Est. completion 2022-06-23 1 site Stand-alone
    Heart failure Other conditions: Myocardial Dysfunction, Inflammation
    View official trial listing →
  • Status unknown NCT NCT05333159

    The Efficacy of SGLT-2 Inhibitor in Patients With CAD and DM Undergoing PCI.

    Beijing Anzhen Hospital 1424 participants Est. completion 2024-12-30 1 site
    Cardiovascular disease Other conditions: Diabete Mellitus
    View official trial listing →
  • Completed NCT NCT05335629

    Evaluation of the Effect of SGLT-2 Inhibitors on Cardiac Remodeling in Post Myocardial Infarction Patients

    Not yet reported Ain Shams University 54 participants Est. completion 2023-10-01 1 site
    Cardiovascular diseaseType 2 diabetes Other conditions: Myocardial Remodeling, Ventricular
    View official trial listing →
  • Status unknown NCT NCT05347459

    Cognitive Protective Effect of Newer Antidiabetic Drugs

    Alexandria University 100 participants Est. completion 2023-12 1 site
    Type 2 diabetes
    View official trial listing →
  • Enrolling by invitation NCT NCT05374291

    The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD

    Not yet reported University Medical Center Groningen 1750 participants Est. completion 2027-07 102 sites Stand-alone
    Heart failure Other conditions: Kidney Disease, Chronic, Renal Transplant Failure, Kidney Failure, Death
    View official trial listing →
  • Terminated NCT NCT05392959

    Effect of the Antidiabetic Drug Dapagliflozin on the Coronary Macrovascular and Microvascular Function in Type 2 Diabetic Patients

    Not yet reported Centre Hospitalier Universitaire Saint Pierre 4 participants Est. completion 2023-07-17 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT05403281

    A Pharmacokinetic Study of DW6012 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers

    Not yet reported Dong Wha Pharmaceutical Co. Ltd. 41 participants Est. completion 2022-03-28 1 site Stand-alone
    Other conditions: Healthy Subjects
    View official trial listing →
  • Completed NCT NCT05411965

    A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C.

    Not yet reported Boryung Pharmaceutical Co., Ltd 48 participants Est. completion 2022-07-03 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT05418465

    Huangqi Guizhi Wuwu Decoction in CKD Stage 2-4 Diabetic Nephropathy

    Not yet reported The First Affiliated Hospital of Dalian Medical University 100 participants Est. completion 2022-12-31 1 site
    Other conditions: Diabetic Nephropathies
    View official trial listing →
  • Status unknown NCT NCT05418946

    The Effects of Dapagliflozin in Normal Clinical Practice in T2D

    University of Milan 1400 participants Est. completion 2022-12 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT05424315

    Impact of DApagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-Diabetic Patients

    Not yet reported, Not yet reported Omar Younis 100 participants Est. completion 2022-04-30 2 sites
    Other conditions: Anterior MI
    View official trial listing →
  • Status unknown NCT NCT05443932

    Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients

    Not yet reported Medical University of Vienna 32 participants Est. completion 2025-12-31 1 site
    Other conditions: Urolithiasis, Hyperoxaluria
    View official trial listing →
  • Completed NCT NCT05453786

    A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers

    Not yet reported SK Chemicals Co., Ltd. 51 participants Est. completion 2022-08-11 1 site
    Other conditions: Healthy Subjects
    View official trial listing →
  • Completed NCT NCT05457933

    Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes

    Not yet reported Medanta, The Medicity, India 250 participants Est. completion 2023-01-14 1 site Stand-alone
    Cardiovascular disease Other conditions: Type2diabetes
    View official trial listing →
  • Completed NCT NCT05459701

    Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)

    Not yet reported Rehab Werida 50 participants Est. completion 2024-07-31 1 site
    MASLDType 2 diabetes
    View official trial listing →
  • Completed NCT NCT05465213

    Real-world Dapagliflozin Treatment in Patients With Heart Failure in Portugal (EVOLUTION-HF)

    AstraZeneca 283 participants Est. completion 2024-06-24 8 sites
    Heart failure
    View official trial listing →
  • Terminated NCT NCT05468203

    PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care

    Not yet reported The George Institute 51 participants Est. completion 2025-12-23 3 sites Stand-alone
    Other conditions: Acute Kidney Injury
    View official trial listing →
  • Status unknown NCT NCT05520684

    Asymptomatic Bacteriuria, Urinalysis Abnormality at the Initiation of SGLT2 Inhibitors and UTI Risk

    Trabzon Arakli Bayram Halil Public Hospital 120 participants Est. completion 2023-01-01 1 site
    Other conditions: Type2diabetes, SGLT2 Inhibitor, Urinary Tract Infection
    View official trial listing →
  • Status unknown NCT NCT05550441

    Effect of Dapagliflozin on VT in Patients With Heart Failure.

    Not yet reported Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 120 participants Est. completion 2024-11-15 Stand-alone
    Heart failure
    View official trial listing →
  • Completed NCT NCT05558098

    Dapagliflozin in Patients With Critical Illness

    Not yet reported Hospital Israelita Albert Einstein 507 participants Est. completion 2023-10-20 23 sites
    Other conditions: Critical Illness, Sepsis
    View official trial listing →
  • Status unknown NCT NCT05565976

    Dapagliflozin Effect in Cognitive Impairment in Stroke Trial

    Not yet reported, Not yet reported Jaime Daniel Mondragon 270 participants Est. completion 2025-07-01 1 site Stand-alone
    Cardiovascular diseaseMetabolic syndrome Other conditions: Mild Cognitive Impairment, Dementia, Vascular
    View official trial listing →
  • Completed NCT NCT05570305

    Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria

    Not yet reported University Medical Center Groningen 42 participants Est. completion 2025-03-05 7 sites Stand-alone
    Chronic kidney disease
    View official trial listing →
  • Active, not recruiting NCT NCT05590143

    proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2

    Not yet reported Amsterdam UMC 784 participants Est. completion 2025-09 6 sites Stand-alone
    Other conditions: Acute Kidney Injury, Cardiac Surgery, Sodium-Glucose Transporter 2 Inhibitor
    View official trial listing →
  • Status unknown NCT NCT05591235

    Effect of Metformin, Dapagliflozin, Combination of Metformin and Pioglitazone in Patients With Type 2 Diabetes

    Not yet reported Nanjing First Hospital, Nanjing Medical University 60 participants Est. completion 2023-02
    Other conditions: Type2diabetes, Insulin Resistance
    View official trial listing →
  • Status unknown NCT NCT05601336

    of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic, Hormonal and Clinical Parameters in PCO

    Not yet reported Beni-Suef University 200 participants Est. completion 2023-07-30 1 site
    Other conditions: PCO
    View official trial listing →
  • Status unknown NCT NCT05618223

    Dapagliflozin Effect on Rheumatic Mitral Stenosis

    Not yet reported Universitas Sebelas Maret 36 participants Est. completion 2023-06-30 1 site Stand-alone
    Heart failure Other conditions: Rheumatic Heart Disease, Mitral Stenosis
    View official trial listing →
  • Completed NCT NCT05621551

    Dapagliflozin Therapy In Cardiac Surgery

    Not yet reported China National Center for Cardiovascular Diseases 178 participants Est. completion 2025-06-01 1 site Stand-alone
    Type 2 diabetes Other conditions: Cardiac Surgery
    View official trial listing →
  • Completed NCT NCT05635331

    Real-world Dapagliflozin Experience in Patients With Heart Failure in Greece

    AstraZeneca 257 participants Est. completion 2024-12-03 16 sites
    Heart failure
    View official trial listing →
  • Active, not recruiting NCT NCT05637853

    Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction

    Not yet reported Göteborg University 60 participants Est. completion 2026-08-26 1 site Stand-alone
    Heart failure
    View official trial listing →
  • Status unknown NCT NCT05685394

    DApagliflozin Cardiovascular Effects on Patients at End-stage REnal Disease

    Not yet reported University of Campinas, Brazil 80 participants Est. completion 2024-12-01 1 site Stand-alone
    Other conditions: End-stage Kidney Disease
    View official trial listing →
  • Completed NCT NCT05704088

    SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients

    Not yet reported Mansoura University 100 participants Est. completion 2024-01-08 1 site
    Other conditions: SGLT2 INHIBITORS, Lupus Nephritis, BMD
    View official trial listing →
  • Status unknown NCT NCT05710367

    Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients

    Not yet reported Albina Nowak, MD 46 participants Est. completion 2024-08 Stand-alone
    Other conditions: Fabry Disease
    View official trial listing →
  • Status unknown NCT NCT05713851

    Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease (CKD) Transition: DAKI-CKD Study

    Not yet reported, Not yet reported Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran 100 participants Est. completion 2025-01-01 1 site Stand-alone
    Chronic kidney disease Other conditions: AKI - Acute Kidney Injury, Biomarkers
    View official trial listing →
  • Active, not recruiting NCT NCT05719714

    Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

    Not yet reported, Not yet reported Northwestern University 18 participants Est. completion 2026-09-30 1 site Stand-alone
    Chronic kidney diseaseHeart failure Other conditions: Kidney Diseases
    View official trial listing →
  • Status unknown NCT NCT05727423

    Dapagliflozin in the Treatment of Heart Failure

    Helwan University 45 participants Est. completion 2024-02-01 1 site
    Heart failure
    View official trial listing →
  • Completed NCT NCT05735197

    Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients

    Not yet reported Mansoura University 100 participants Est. completion 2023-11-01 1 site
    Chronic kidney disease Other conditions: Bone Diseases, Metabolic
    View official trial listing →
  • Terminated NCT NCT05737186

    SGLT2 Inhibitors and Treatment of Heart Failure in Severe Renal Insufficiency

    Not yet reported Peking University People's Hospital 11 participants Est. completion 2024-04-16 1 site Stand-alone
    Heart failure Other conditions: Renal Insufficiency, Chronic
    View official trial listing →
  • Status unknown NCT NCT05759000

    Dapa Acute Heart Failure Study

    Chinese University of Hong Kong 100 participants Est. completion 2025-12-09 1 site
    Heart failure
    View official trial listing →
  • Status unknown NCT NCT05770167

    Effects of Dapagliflozin on Cardiorespiratory Parameters in Heart Failure

    Centro Cardiologico Monzino 70 participants Est. completion 2025-04 1 site
    Heart failure Other conditions: Left Ventricle Remodeling, Sleep Apnea, Cardiopulmonary Exercise Test
    View official trial listing →
  • Status unknown NCT NCT05776043

    Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure

    Not yet reported Medical University of Warsaw 1364 participants Est. completion 2025-12-31 1 site
    Heart failure
    View official trial listing →
  • Active, not recruiting NCT NCT05782972

    Therapeutic Response of Sodium-glucose Co-transporter Type-2 Inhibitor in Non-diabetic MAFLD Patients: a Pilot Study

    Not yet reported Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation 50 participants Est. completion 2025-12-31 1 site Stand-alone
    Other conditions: Metabolic Associated Fatty Liver Disease
    View official trial listing →
  • Completed NCT NCT05792540

    Clinical Study to Evaluate the Possible Efficacy of Dapagliflozin and Atorvastatin in Patients With Major Depressive Disorders

    Not yet reported Tanta University 75 participants Est. completion 2024-12-20 1 site
    Other conditions: Depressive Disorder
    View official trial listing →
  • Completed NCT NCT05797935

    Evaluation of Changes in Pancreatic Fat Content Using Advanced MR Sequences in Diabetics on Dapagliflozin Therapy

    Not yet reported Post Graduate Institute of Medical Education and Research, Chandigarh 50 participants Est. completion 2022-12-31 1 site
    Other conditions: Pancreatic Lipomatosis
    View official trial listing →
  • Withdrawn NCT NCT05833958

    Polypill Versus Metformin in New Onset Type 2 Diabetes

    Not yet reported George Medicines PTY Limited Est. completion 2025-09 Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT05848102

    Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Fibrosis (DEFORM)

    Not yet reported Sun Yat-sen University 166 participants Est. completion 2025-04-23 3 sites Stand-alone
    Other conditions: Functional Mitral Regurgitation
    View official trial listing →
  • Status unknown NCT NCT05849220

    Dapagliflozin in Non Alcoholic Fatty Liver Disease Associated Cirrhosis and Its Role in Preventing Development of Chronic Kidney Disease.

    Not yet reported Institute of Liver and Biliary Sciences, India 144 participants Est. completion 2024-03-30 1 site Stand-alone
    MASLD
    View official trial listing →
  • Completed NCT NCT05884866

    A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease.

    Not yet reported Klinikum Nürnberg 103 participants Est. completion 2026-01-28 2 sites Stand-alone
    Chronic kidney disease Other conditions: Chronic Renal Failure, Mechanistic Effects of SGLT2 Inhibition and/ or MR Antagonism on Body Fluid and Electrolyte Homeostatis, Electrolyte and Fluid Balance Conditions
    View official trial listing →
  • Not yet recruiting NCT NCT05886088

    Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus

    Not yet reported EMS 597 participants Est. completion 2027-01 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT05915949

    Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and Safety

    Not yet reported Seoul National University Bundang Hospital 99 participants Est. completion 2023-12-31 1 site Stand-alone
    Other conditions: Diabetes Type 2
    View official trial listing →
  • Completed NCT NCT05932901

    OPTIMISE-CKD Drug Utilization

    AstraZeneca 2682052 participants Est. completion 2023-09-28 5 sites
    Chronic kidney disease
    View official trial listing →
  • Status unknown NCT NCT05965934

    Management of Volume Overload HF Patients by Individual DSR Treatment adJustment-a clinicAl inVestigation of InfusatE2.0

    Not yet reported, Not yet reported Sequana Medical N.V. 33 participants Est. completion 2025-06-30 1 site
    Heart failure Other conditions: Volume Overload
    View official trial listing →
  • Status unknown NCT NCT05966818

    Effect of Dapagliflozin in Non-Diabetic Patients With Nephrotic Syndrome.

    Not yet reported Ain Shams University 90 participants Est. completion 2024-03-01
    Other conditions: Nephrotic Syndrome
    View official trial listing →
  • Completed NCT NCT05989503

    Initiation of ARNi and SGLT2i in Patients With HFrEF

    Not yet reported Universidade do Porto 62 participants Est. completion 2025-07-31 5 sites
    Heart failure
    View official trial listing →
  • Completed NCT NCT05993897

    Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling

    Not yet reported Aswan University 60 participants Est. completion 2025-10-15 1 site
    Other conditions: Atrial Fibrillation
    View official trial listing →
  • Completed NCT NCT05998525

    Dapagliflozin Effects on Coronary Calcium and Epicardial Fat Assessed by Cardiotomography

    Not yet reported Hilda Elizabeth Macías Cervantes 54 participants Est. completion 2023-06-01 1 site Stand-alone
    Cardiovascular diseaseType 2 diabetes Other conditions: Diabete Type 2, Unstable Angina
    View official trial listing →
  • Active, not recruiting NCT NCT06000462

    The Effect of Dapagliflozin on Weight Loss in Obese Adults Without Diabetes

    Not yet reported Oman Ministry of Health 150 participants Est. completion 2025-12-30 1 site Stand-alone
    Other conditions: Obesity, Dapagliflozin Adverse Reaction, Weight Loss, Effect of Drug
    View official trial listing →
  • Status unknown NCT NCT06009874

    Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMI

    Not yet reported Mohammad Hussien Tantawy Soliman 80 participants Est. completion 2026-08 1 site
    Cardiovascular disease
    View official trial listing →
  • Status unknown NCT NCT06012266

    Repurposing Empagliflozin and Dapagliflozin for Paediatric Heart Failure: Translational Approach and Dose Rationale

    Not yet reported Centre Hospitalier Universitaire Vaudois 12 participants Est. completion 2025-08 3 sites
    Heart failure
    View official trial listing →
  • Completed NCT NCT06012279

    Clinical Outcomes of Dapagliflozin in Acute Heart Failure With Reduced Ejection Fraction (CODA-HFrEF)

    Not yet reported Cairo University 117 participants Est. completion 2024-02-26 2 sites Stand-alone
    Heart failure
    View official trial listing →
  • Completed NCT NCT06063109

    A Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of Telmisartan and Dapagliflozin.

    Not yet reported THPharm Corp. 51 participants Est. completion 2023-11-09 1 site Stand-alone
    Type 2 diabetes Other conditions: Hypertension
    View official trial listing →
  • Completed NCT NCT06065280

    Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients

    Not yet reported Damanhour University 80 participants Est. completion 2024-12-30 1 site Stand-alone
    Heart failure
    View official trial listing →
  • Not yet recruiting NCT NCT06072326

    dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation

    Not yet reported University Medical Center Groningen 36 participants Est. completion 2028-12 7 sites Stand-alone
    Chronic kidney disease
    View official trial listing →
  • Active, not recruiting NCT NCT06087835

    Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

    Not yet reported AstraZeneca 1835 participants Est. completion 2027-02-18 296 sites Stand-alone
    Chronic kidney disease
    View official trial listing →
  • Completed NCT NCT06090487

    Is Sacubitril-valsartan Superior to Dapagliflozin in Improving Myocardial Function Performance

    Not yet reported Ain Shams University 30 participants Est. completion 2024-03-01 1 site
    Heart failure
    View official trial listing →
  • Terminated NCT NCT06094231

    Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study

    Not yet reported Department of Nephrology Clinic Ottakring Vienna 4 participants Est. completion 2026-04-13 1 site Stand-alone
    Chronic kidney diseasePrediabetes Other conditions: Diabetes Mellitus, Overweight and Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT06111443

    Effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation

    Not yet reported, Not yet reported Chang Gung Memorial Hospital 196 participants Est. completion 2026-11-30 1 site Stand-alone
    Other conditions: Atrial Fibrillation Recurrent, Catheter Ablation
    View official trial listing →
  • Status unknown NCT NCT06113900

    Assessment of Safety and Efficacy of SGLT2is Among LN Patients

    Not yet reported, Not yet reported Ain Shams University 50 participants Est. completion 2025-01-30 1 site Stand-alone
    Other conditions: Lupus Nephritis
    View official trial listing →
  • Completed NCT NCT06117137

    The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus

    Not yet reported Sohag University 150 participants Est. completion 2026-04-03 1 site Stand-alone
    Other conditions: Fatty Liver, Nonalcoholic
    View official trial listing →
  • Status unknown NCT NCT06127433

    The Effect of Short-term Insulin Intensive Therapy Based on the Application of Insulin Pump and Real-time Dynamic Glucose Monitoring Technology on Reversing the Newly Diagnosed Type 2 Diabetes

    Not yet reported Sun Yat-sen University 210 participants Est. completion 2024-12-30 1 site
    Other conditions: Insulin Pump，Continuous Glucose Monitoring Technology
    View official trial listing →
  • Status unknown NCT NCT06128096

    The Effect of SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac Function in T2DM Patients With CAD (EpiCAD)

    Clinical Research Centre, Malaysia 360 participants Est. completion 2024-12-31 1 site
    Cardiovascular disease
    View official trial listing →
  • Status unknown NCT NCT06147271

    Impact of SGLT2 Inhibitors in Heart Transplant Recipients

    Not yet reported Universidade Federal do Ceara 80 participants Est. completion 2025-08-01 1 site
    Other conditions: Transplant; Failure, Heart, Cardiac Allograft Vasculopathy, Rejection Heart Transplant
    View official trial listing →
  • Status unknown NCT NCT06147518

    To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis

    Not yet reported Institute of Liver and Biliary Sciences, India 240 participants Est. completion 2024-12-31 1 site Stand-alone
    Other conditions: Compensated Cirrhosis, Decompensated Cirrhosis
    View official trial listing →
  • Completed NCT NCT06148259

    SGLT Inhibitors Versus DDP4 Inhibitors and Prostate in Patient With Diabetes

    Not yet reported Kasr El Aini Hospital 57 participants Est. completion 2022-09-13 2 sites
    Other conditions: Diabetes Mellitus, Prostatic Hyperplasia
    View official trial listing →
  • Status unknown NCT NCT06187493

    Treatment of Patients With Diabetic Kidney Disease

    Not yet reported Assiut University 70 participants Est. completion 2025-12-31
    Chronic kidney disease
    View official trial listing →
  • Status unknown NCT NCT06201000

    Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients

    October 6 University 282 participants Est. completion 2024-09-01 1 site
    Heart failure Other conditions: Genetic Polymorphisms
    View official trial listing →
  • Completed NCT NCT06203704

    Observational Secondary Data Study Describing Treatment With Dapagliflozin Among Adult Chronic Kidney Disease Patients

    AstraZeneca 1086 participants Est. completion 2025-09-30 56 sites
    Chronic kidney disease
    View official trial listing →
  • Active, not recruiting NCT NCT06226896

    Effects of Dapagliflozin on Progression of Alport Syndrome

    Nanjing University School of Medicine 222 participants Est. completion 2026-09-30 1 site
    Other conditions: Alport Syndrome
    View official trial listing →
  • Status unknown NCT NCT06233045

    Dapagliflozin Tablet 10 mg Relative to Forxiga® Tablets 10 mg

    Not yet reported Bio-innova Co., Ltd 30 participants Est. completion 2024-09-08 Stand-alone
    Other conditions: Healthy Subjects
    View official trial listing →
  • Status unknown NCT NCT06251453

    Impact of Sodium-glucose Cotransporter 2 Inhibitors on Post-operative Atrial Fibrillation in Cardiothoracic Surgery

    Hamad Medical Corporation 3280 participants Est. completion 2025-01-31 2 sites
    Other conditions: Atrial Fibrillation
    View official trial listing →
  • Active, not recruiting NCT NCT06268873

    A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

    Not yet reported AstraZeneca 2554 participants Est. completion 2028-02-24 565 sites Stand-alone
    Chronic kidney disease
    View official trial listing →
  • Status unknown NCT NCT06281899

    Effect of Low Protein Diet on Top of Dapagliflozin on Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus

    Not yet reported Anemia Working Group Romania 200 participants Est. completion 2025-03-31 1 site Stand-alone
    Chronic kidney diseaseType 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT06297681

    Combination of Daratumumab and BD Regimen and Dapagliflozin in the Treatment of M-protein Related Cardiac Disease

    Beijing Chao Yang Hospital 40 participants Est. completion 2025-12-31
    Other conditions: M-protein Related Cardiac Disease
    View official trial listing →
  • Active, not recruiting NCT NCT06317051

    Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)

    Not yet reported Kirby Institute 300 participants Est. completion 2027-12 10 sites
    Other conditions: HIV Infections, Weight Gain
    View official trial listing →
  • Completed NCT NCT06326034

    Impact of Dapagliflozin as Add-on Therapy on Glycemic Status and Quality of Life in Type 2 Diabetic Patients

    Not yet reported Mohammed Mahmood Mohammed 40 participants Est. completion 2023-01-01 1 site Stand-alone
    Chronic kidney disease
    View official trial listing →
  • Status unknown NCT NCT06326528

    SGLT2 Inhibitors and Perioperative Period

    Assiut University 100 participants Est. completion 2025-10-01
    Other conditions: Perioperative Complication
    View official trial listing →
  • Completed NCT NCT06327815

    Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM

    Not yet reported AstraZeneca 633 participants Est. completion 2025-06-30 35 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT06365541

    The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients

    Not yet reported The People's Hospital of Gaozhou 40 participants Est. completion 2024-08-31 1 site Stand-alone
    Heart failure
    View official trial listing →
  • Completed NCT NCT06370247

    First-time Usage of SGLT2 Inhibitors in Type 2 Diabetic Patients Who Are Fasting During Ramadan: Safety and Efficacy

    Not yet reported Sohag University 60 participants Est. completion 2023-09-25 1 site
    Type 2 diabetes Other conditions: SGLT2 Inhibitors, First Time Use, Fasting in Ramadan
    View official trial listing →
  • Completed NCT NCT06374043

    Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.

    Not yet reported University Medical Center Groningen 20 participants Est. completion 2022-09-13 2 sites
    Type 2 diabetesChronic kidney disease Other conditions: Diabetes Mellitus, Diabetes, Diabetes Complications, Albuminuria, Proteinuria
    View official trial listing →
  • Completed NCT NCT06405178

    Adjuvant Therapy With Letrozole in Induction of Ovulation With Polycystic Ovarian Syndrome

    Not yet reported Beni-Suef University 200 participants Est. completion 2026-04-01 1 site Stand-alone
    Other conditions: Polycystic Ovary
    View official trial listing →
  • Completed NCT NCT06415773

    Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

    Not yet reported Shenzhen HighTide Biopharmaceutical Ltd. 367 participants Est. completion 2025-07-25 53 sites
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT06417320

    Effect of Sodium-glucose Cotransporter-2 Inhibitors (SGLT-2i) on Proteinuria in Nephrotic Children Older Than 10 Years

    Not yet reported Mansoura University 60 participants Est. completion 2025-08 1 site
    Other conditions: Nephrotic Syndrome in Children
    View official trial listing →
  • Status unknown NCT NCT06421870

    Renoprotective Effects of Dapagliflozin Versus Pentoxiphylline in Chronic Kidney Disease Patients

    Not yet reported Ain Shams University 210 participants Est. completion 2025-07 1 site
    Chronic kidney disease
    View official trial listing →
  • Completed NCT NCT06433479

    Efficacy of Dapagliflozin on Recurrence After Catheter Ablation for Atrial Fibrillation

    Not yet reported Beijing Anzhen Hospital 200 participants Est. completion 2025-07-01 1 site Stand-alone
    Other conditions: Atrial Fibrillation
    View official trial listing →
  • Not yet recruiting NCT NCT06434025

    IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency

    Not yet reported Hospital de Clinicas de Porto Alegre 99 participants Est. completion 2026-11-24 1 site Stand-alone
    Heart failure Other conditions: Iron Deficiencies
    View official trial listing →
  • Status unknown NCT NCT06442280

    SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF

    Not yet reported University of Palermo 544 participants Est. completion 2026-03-30 Stand-alone
    Heart failure Other conditions: Diabetes Type 2
    View official trial listing →
  • Status unknown NCT NCT06449235

    Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

    Not yet reported Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders 938 participants Est. completion 2025-06 1 site
    Other conditions: Type2diabetes
    View official trial listing →
  • Completed NCT NCT06453577

    Pharmacokinetics of Bisoprolol and SGLT2i in Acutely Decompensated Heart Failure

    Universität des Saarlandes 33 participants Est. completion 2026-07-08 1 site
    Heart failure
    View official trial listing →
  • Status unknown NCT NCT06510270

    Dapagliflozin in Reducing Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction

    Not yet reported Aswan University 70 participants Est. completion 2025-10-01
    Heart failure
    View official trial listing →
  • Active, not recruiting NCT NCT06532682

    Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes

    Not yet reported The First Affiliated Hospital with Nanjing Medical University 54 participants Est. completion 2026-10-01 1 site Stand-alone
    Chronic kidney disease Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT06589765

    A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin

    Not yet reported Shandong Suncadia Medicine Co., Ltd. 810 participants Est. completion 2026-05-29 1 site
    Type 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT06610526

    A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease

    Not yet reported AstraZeneca 731 participants Est. completion 2027-05-31 34 sites Stand-alone
    Chronic kidney disease
    View official trial listing →
  • Completed NCT NCT06614712

    OPTIMISE-CKD Study_current Clinical Landscape in Spain

    AstraZeneca 91628 participants Est. completion 2025-10-06 1 site
    Other conditions: Renal Disease
    View official trial listing →
  • Completed NCT NCT06615674

    Effect of Dapagliflozin Administration on the Apoptosis Levels of Patients With Acute Myocardial Infarction

    Not yet reported Yoga Yudhistira 40 participants Est. completion 2024-12-07 1 site Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Active, not recruiting NCT NCT06619600

    Effect of Dapagliflozin in Myocardial Fibrosis and Ventricular Function in Patients With a ST-segment Elevation Myocardial Infarction

    Not yet reported Hospital Clinic of Barcelona 54 participants Est. completion 2025-03-31 2 sites Stand-alone
    Cardiovascular diseaseHeart failure Other conditions: Diabetes Mellitus, Myocardial Fibrosis
    View official trial listing →
  • Completed NCT NCT06651021

    A Phase I PK Study of Balcinrenone/Dapagliflozin in Healthy Chinese Participants

    Not yet reported AstraZeneca 10 participants Est. completion 2024-10-28 1 site Stand-alone
    Other conditions: Healthy Volunteer
    View official trial listing →
  • Status unknown NCT NCT06679179

    Effect of Flozin (dapagliflozin) Administration on Myocardial and Peripheral Vascular Remodeling

    Poznan University of Medical Sciences 50 participants Est. completion 2026-02-28 1 site
    Heart failure
    View official trial listing →
  • Completed NCT NCT06697353

    An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan

    Bayer 4936 participants Est. completion 2025-09-19 1 site
    Heart failure
    View official trial listing →
  • Not yet recruiting NCT NCT06740786

    Efficacy and Safety of Dapagliflozin in Preventing Atrial Fibrillation Recurrence After Catheter Ablation

    Not yet reported Xu Liu 250 participants Est. completion 2026-05-01 Stand-alone
    Other conditions: Atrial Fibrillation (AF)
    View official trial listing →
  • Completed NCT NCT06778330

    The Effect of Combination of Dapagliflozin and Sildenafil in Treatment of Heart Failure Patients With Secondary Pulmonary Hypertension

    Not yet reported Fayoum University 100 participants Est. completion 2025-08-01 1 site
    Heart failure
    View official trial listing →
  • Completed NCT NCT06797115

    Hydroxyl Free Radical Associated Effects of SGLT-2 Inhibitors in Type 2 Diabetes

    University of Pecs 40 participants Est. completion 2024-06-30 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT06812429

    Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation

    Not yet reported Washington University School of Medicine 6 participants Est. completion 2025-04-05 1 site Stand-alone
    Other conditions: Inflammation
    View official trial listing →
  • Not yet recruiting NCT NCT06820567

    Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients With Type 2 Diabetes and CKD

    Not yet reported Assiut University 210 participants Est. completion 2027-05-01
    Chronic kidney disease Other conditions: Diabetes Type 2
    View official trial listing →
  • Completed NCT NCT06831864

    Heart Failure With Reduced Ejection Fraction Polypill Implementation Strategy in Sri Lanka

    Not yet reported Washington University School of Medicine 40 participants Est. completion 2025-05-05 2 sites Stand-alone
    Heart failure
    View official trial listing →
  • Completed NCT NCT06851962

    Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.

    Not yet reported Fundación para la Investigación del Hospital Clínico de Valencia 92 participants Est. completion 2026-06-30 3 sites Added to GLP-1
    Type 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT06907251

    Dapagliflozin for Long COVID Syndrome

    Not yet reported Ottawa Heart Institute Research Corporation 192 participants Est. completion 2029-06-30 1 site Stand-alone
    Other conditions: COVID - 19, Long COVID Syndrome, SARS CoV-2
    View official trial listing →
  • Completed NCT NCT06915870

    Comparison of Empagliflozin and Dapagliflozin in Patients With Heart Failure Taking Standard Treatment

    Not yet reported Fatima Maqsood 108 participants Est. completion 2025-01-13 1 site Stand-alone
    Heart failure Other conditions: Diabetes Mellitus
    View official trial listing →
  • Not yet recruiting NCT NCT06922656

    Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?

    Not yet reported Dasman Diabetes Institute 60 participants Est. completion 2027-01-15 3 sites
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Enrolling by invitation NCT NCT06954090

    Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study

    Not yet reported Steno Diabetes Center Copenhagen 50 participants Est. completion 2027-05-31 1 site
    Chronic kidney disease Other conditions: Type 2 DM, Albuminuria
    View official trial listing →
  • Completed NCT NCT06964607

    Impact of Sodium Glucose Co-transporter 2-Inhibitors on Clinical Outcome and Left Ventricular Function in Patients Presented by Acute Myocardial Infarction

    Tanta University 80 participants Est. completion 2024-04-01 1 site
    Cardiovascular disease Other conditions: Sodium-glucose Cotransporter 2, Inhibitors, Clinical Outcome, Left Ventricule
    View official trial listing →
  • Completed NCT NCT06979388

    A Study to Investigate the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants.

    Not yet reported AstraZeneca 14 participants Est. completion 2025-07-12 1 site Stand-alone
    Other conditions: Healthy Participants
    View official trial listing →
  • Active, not recruiting NCT NCT07020377

    Dapagliflozin in Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus Patients (T2DM).

    Not yet reported, Not yet reported Amira Bisher,PhD 60 participants Est. completion 2025-12-30 2 sites
    Other conditions: Diabetes Mellitus, Non Alcholic Fatty Liver Disease
    View official trial listing →
  • Active, not recruiting NCT NCT07026968

    A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes

    Not yet reported CSPC Ouyi Pharmaceutical Co., Ltd. 815 participants Est. completion 2026-11-13 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT07033585

    Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers

    Not yet reported, Not yet reported Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair 600 participants Est. completion 2026-11-28 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07034781

    A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults

    Not yet reported AJU Pharm Co., Ltd. 50 participants Est. completion 2025-11 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07044765

    A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults: Fed State Study

    Not yet reported AJU Pharm Co., Ltd. 32 participants Est. completion 2025-11 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT07077525

    Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors

    Not yet reported Al-Azhar University 196 participants Est. completion 2024-08-31 1 site
    Type 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07105917

    SLGT2i for Neuroprotection in Patients With Acute Ischemic Stroke

    Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 1050 participants Est. completion 2026-11-01 Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Not yet recruiting NCT NCT07108985

    Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors

    Not yet reported Yonsei University 100 participants Est. completion 2030-08-31 1 site Stand-alone
    Type 2 diabetes Other conditions: Hyperglycemia, Insulin Resistance
    View official trial listing →
  • Completed NCT NCT07120828

    The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity

    Not yet reported Erbil Polytechnic University 260 participants Est. completion 2026-03-15 1 site Stand-alone
    Type 2 diabetes Other conditions: Obese Diabetics, Obese Patients (BMI ≥ 30 kg/m²)
    View official trial listing →
  • Not yet recruiting NCT NCT07186153

    Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling in Diabetic Patients

    Assiut University 100 participants Est. completion 2026-11-01
    Other conditions: SGLT 2 Inhibitors
    View official trial listing →
  • Active, not recruiting NCT NCT07188545

    Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

    Ohio State University 23280000 participants Est. completion 2029-06-30 1 site
    Metabolic syndrome
    View official trial listing →
  • Active, not recruiting NCT NCT07198191

    SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study

    Yonsei University 200000 participants Est. completion 2026-08-30 1 site
    Cardiovascular diseaseType 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT07204743

    Efficacy and Safety of Dapagliflozin in Children With Proteinuria

    Not yet reported Al-Quds University 10 participants Est. completion 2026-08 1 site Stand-alone
    Other conditions: SGLT 2 Inhibitors, Pediatric Kidney Disease, Proteinuric Diseases, Dapagliflozin (Forxiga)
    View official trial listing →
  • Not yet recruiting NCT NCT07206160

    Effect of Dapagliflozin on Interleukin 10 in Sepsis

    Minia University 64 participants Est. completion 2026-11-01
    Other conditions: Sepsis
    View official trial listing →
  • Completed NCT NCT07210307

    Safety Of DAPAGLIFLOZIN (FORXIGA) in Patient With Type 2 Diabetes Mellitus (T2dm) In Vietnam From A Post-Marketing Surveillance Program

    AstraZeneca 1001 participants Est. completion 2020-03-17 1 site
    Other conditions: Safety Outcomes
    View official trial listing →
  • Active, not recruiting NCT NCT07222917

    A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.

    Not yet reported AstraZeneca 222 participants Est. completion 2026-12-10 55 sites Stand-alone
    Chronic kidney disease
    View official trial listing →
  • Completed NCT NCT07269197

    Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes

    Josip Juraj Strossmayer University of Osijek 67 participants Est. completion 2025-10-10 1 site
    Type 2 diabetes Other conditions: Non-Alcoholic Fatty Liver Disease
    View official trial listing →
  • Not yet recruiting NCT NCT07272057

    SGLT2 Inhibitors and Survival in Lung Cancer Patients With Diabetes

    Not yet reported Shanghai Chest Hospital 200 participants Est. completion 2026-11-07 Stand-alone
    Other conditions: Lung Cancer
    View official trial listing →
  • Completed NCT NCT07302464

    Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic Versus Non-Diabetic Chronic Kidney Disease Patients

    Ain Shams University 60 participants Est. completion 2025-06-01 1 site
    Chronic kidney disease Other conditions: Sodium Glucose Co-Transporter 2 Inhibitors, Estimated Glomerular Filtration Rate, Diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07310433

    Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer

    Not yet reported Yung NA 60 participants Est. completion 2030-10-30 2 sites Stand-alone
    Other conditions: Prostate Cancer, Metastatic Prostate Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07311551

    A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)

    Not yet reported Bhavya Bhavya, MD 112 participants Est. completion 2026-12 Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT07325435

    Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

    Not yet reported MaryAnn Banerji 60 participants Est. completion 2028-06-30 1 site
    Type 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07331727

    Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation

    Not yet reported Shanghai Chest Hospital 280 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: Atrial Fibrillation (AF)
    View official trial listing →
  • Completed NCT NCT07333742

    A Clinical Study to See How the Body Handles and How Safe a Combination Tablet of Gemigliptin, Dapagliflozin, and Metformin 50/10/1000mg is Compared to Taking Gemigliptin 50mg Separately With Dapagliflozin/Metformin 10/1000mg in Healthy Adults After a Meal

    Not yet reported LG Chem 50 participants Est. completion 2025-11-27 1 site Stand-alone
    Other conditions: Fed Conditions, Healthy Volunteer
    View official trial listing →
  • Not yet recruiting NCT NCT07334145

    Effect of SGLT2 Inhibitors on Anemic CKD Patients

    Sohag University 60 participants Est. completion 2026-09-01 1 site
    Chronic kidney disease
    View official trial listing →
  • Not yet recruiting NCT NCT07342764

    Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A Pragmatic Pilot Randomized Controlled Trial

    Not yet reported Sultan Qaboos University 110 participants Est. completion 2028-12 1 site Stand-alone
    Other conditions: Antipsychotic-induced Weight Gain (AIWG), Antipsychotic-induced Weight Gain
    View official trial listing →
  • Completed NCT NCT07344922

    SGLT2 Inhibitors in Non-Diabetic CKD: Effects on Vascular Calcification and Anemia

    Not yet reported Mansoura University 100 participants Est. completion 2023-12-01 1 site Stand-alone
    Chronic kidney disease Other conditions: Anemia, Cardiovascular Calcification
    View official trial listing →
  • Not yet recruiting NCT NCT07348484

    Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors

    Instituto de Investigación Biomédica de Salamanca 300 participants Est. completion 2028-03 1 site
    Chronic kidney disease
    View official trial listing →
  • Not yet recruiting NCT NCT07351864

    Finerenone Plus SGLT2 Inhibitors in Heart Failure

    Not yet reported Mansoura University 60 participants Est. completion 2026-07-31 1 site Stand-alone
    Heart failure
    View official trial listing →
  • Completed NCT NCT07363707

    A Study Between Dapagliflozin and Empagliflozin Effect on NAFLD in Patients With Type 2 Diabetes.

    Not yet reported Beni-Suef University 108 participants Est. completion 2024-03-01 1 site
    MASLD
    View official trial listing →
  • Not yet recruiting NCT NCT07392151

    Reversal to Normoglycemia by Treating Prediabetes

    Not yet reported Michael Mæng 158 participants Est. completion 2029-10 1 site
    Prediabetes Other conditions: Chronic Coronary Syndrome
    View official trial listing →
  • Completed NCT NCT07396844

    The Food Effect on Pharmacokinetics of Fixed Dose Combination of Gemigliptin/Dapagliflozin/Metformin in Healthy Volunteers

    Not yet reported LG Chem 28 participants Est. completion 2026-06-26 1 site Stand-alone
    Other conditions: Healthy, Fasting, Fed
    View official trial listing →
  • Completed NCT NCT07399470

    A Clinical Study in Healthy Adults to See How the Body Processes and How Safe a Tablet That Combines Gemigliptin, Dapagliflozin, and Metformin is, Compared With Taking Zemiglo and Xigduo XR Together While Fasting.

    Not yet reported LG Chem 58 participants Est. completion 2026-02-06 1 site Stand-alone
    Other conditions: Healthy Volunteers, Fasting Conditions
    View official trial listing →
  • Not yet recruiting NCT NCT07403955

    The Effect of Dapagliflozin on Myocardial Strain in Patients With Acute Heart Failure

    Not yet reported Qilu Hospital of Shandong University 188 participants Est. completion 2028-12 Stand-alone
    Heart failure
    View official trial listing →
  • Not yet recruiting NCT NCT07436663

    Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC

    Not yet reported Tanta University 150 participants Est. completion 2027-12-01
    Other conditions: Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07488689

    Assessing the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic Shock Patients With Microcirculatory Dysfunction

    Not yet reported University Hospital, Strasbourg, France 568 participants Est. completion 2030-07 1 site Stand-alone
    Other conditions: Septic Shock
    View official trial listing →
  • Not yet recruiting NCT NCT07516847

    Dapagliflozin for Anemia in Lower-Risk Myelodysplastic Syndromes

    Not yet reported Seug yun Yoon, MD 37 participants Est. completion 2029-09 Stand-alone
    Other conditions: Myelodysplastic Syndromes (MDS), Anemia
    View official trial listing →
  • Completed NCT NCT07539584

    Adiponectin in Patients With Metabolic Disorders

    Not yet reported Moscow Regional Research and Clinical Institute (MONIKI) 130 participants Est. completion 2024-04-08 1 site Stand-alone
    Type 2 diabetes Other conditions: Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
    View official trial listing →
  • Not yet recruiting NCT NCT07547878

    Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

    Not yet reported Baylor Research Institute 64 participants Est. completion 2029-03-31 1 site
    Chronic kidney diseaseType 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT07555106

    Dapagliflozin in Living-Donor Kidney Transplant Recipients

    Not yet reported University of Guadalajara 54 participants Est. completion 2026-09-30 1 site Stand-alone
    Other conditions: Kidney Transplant, Kidney Transplant Failure
    View official trial listing →
  • Not yet recruiting NCT NCT07590466

    A Study to Compare the Pharmacokinetics and Safety of the ATB-U101 and ATB-U1011+ATB-U1012 and ATB-1011+ATB-1012 in Healthy Caucasian Participants

    Not yet reported Autotelicbio 36 participants Est. completion 2026-08-31 Stand-alone
    Other conditions: Diabete Type 2, Hypertension
    View official trial listing →
  • Not yet recruiting NCT NCT07595289

    DP-DCT 1.0：A Comparative Clinical Study on the Effect of Dapagliflozin Combined With CGM Versus SMBG on Glycemic Control in Patients With Type 2 Diabetes Mellitus Based on the DP-DCT Platform

    Not yet reported The Third Xiangya Hospital of Central South University 120 participants Est. completion 2027-08-01 Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07598864

    "Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD With Type 2 Diabetes"

    Not yet reported Chittagong Medical College 88 participants Est. completion 2027-05-01 1 site Stand-alone
    Chronic kidney disease
    View official trial listing →
  • Completed NCT NCT07610174

    Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves

    Not yet reported Kafrelsheikh University 160 participants Est. completion 2026-04-29 1 site Added to GLP-1
    Heart failure Other conditions: Heart Valve Prosthesis
    View official trial listing →
  • Not yet recruiting NCT NCT07679828

    Polypills Approach for Multiple Cardiovascular Risk Factors

    Not yet reported China Medical University, China 8252 participants Est. completion 2030-03-01 12 sites Stand-alone
    Other conditions: Hypertension, Dyslipidemia, Diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07682350

    SGLT2i Effect on PTDM Development and Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients: A Randomized, Doubleblind, Placebo Controlled, National Multicenter Trial

    Not yet reported Odense University Hospital 184 participants Est. completion 2029-10-01 3 sites
    Other conditions: Kidney Transplant Recipient, Sodium Glucose Co-Transporter 2 Inhibitors, Non-Diabetic Patients, Randomized Controlled Trial (RCT), Placebo Control Design, Post Transplant Diabetes Mellitus
    View official trial listing →
  • Active, not recruiting NCT NCT07694596

    SGLT2 Inhibitors and Cognitive Function in Adults With Type 2 Diabetes (SaveMinD)

    Not yet reported University of Primorska 200 participants Est. completion 2028-04-20 1 site Stand-alone
    Type 2 diabetes Other conditions: Cognitive Dysfunction
    View official trial listing →
  • Not yet recruiting NCT NCT07728318

    Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients

    Not yet reported Akhtar Saeed Medical and Dental College 52 participants Est. completion 2027-05-12
    Type 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07741890

    aDAPt-ANOCA: Dapagliflozin for the Treatment of Angina With Non-Obstructive Coronary Artery Disease (ANOCA)

    Not yet reported The Christ Hospital 120 participants Est. completion 2029-03-01 Stand-alone
    Cardiovascular disease Other conditions: Coronary Microvascular Dysfunction (CMD)
    View official trial listing →
  • Not yet recruiting NCT NCT07778719

    Metformin-Dapagliflozin Effects on IGF-1 in Male T2DM With MASLD

    Not yet reported The 95th Hospital of Putian，Putian, Fujian, China 84 participants Est. completion 2027-12-11 1 site Stand-alone
    Type 2 diabetesMASLD
    View official trial listing →
  • Not yet recruiting NCT NCT07810998

    Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome

    Not yet reported, Not yet reported Tanta University 60 participants Est. completion 2027-05-10
    Other conditions: Poly Cystic Ovary Syndrome
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Dapagliflozin, Dapagliflozin (Forxiga®)

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.